The role of inflammatory mediators in the development of insulin resistance and hepatocellular carcinoma by Ströhle, Peter Dirk
 
 
The role of inflammatory mediators  
in the development  
of  
insulin resistance  
and hepatocellular carcinoma 
 
 
 
 
I n a u g u r a l – D i s s e r t a t i o n 
zur 
Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln 
 
 
 
vorgelegt von 
Peter Dirk Ströhle 
aus Mutlangen 
 
 
Köln 2011 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Berichterstatter/in:  Prof. Dr. Jens C. Brüning 
  Priv. Doz. Dr. F. Thomas Wunderlich 
 
 
 
 
 
 
Tag der mündlichen Prüfung: 25.Januar 2012 
 
 
 
  
 
 
 
„Jedem tiefen Naturforscher muß eine Art religiösen Gefühls naheliegen, weil 
er sich nicht vorzustellen vermag, daß die ungemein feinen Zusammenhänge, 
die er erschaut, von ihm zum erstenmal gedacht werden.“  
 
Albert Einstein (1879 – 1955) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 „Liebe Familie und Freunde, ich schätze eure Geduld und 
Unterstützung, die ihr mir immer entgegengebracht habt. Damit habt ihr 
auch einen großen Teil zu dieser Arbeit beigetragen. Ihr seid 
unbezahlbar!" 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
____________________________________________________________________________________________________________________________ 
 I 
Table of contents: 
 
Table of contents: ........................................................................................... I 
Figure index:...................................................................................................V 
Table index: ..................................................................................................VII 
Abbreviations: .............................................................................................VIII 
 
1. Introduction: ............................................................................................... 1 
1.1 Obesity..............................................................................................................1 
1.2 Energy homeostasis........................................................................................2 
1.2.1 The role of insulin signaling in energy homeostasis ...................................2 
1.2.2 The insulin signaling cascade .....................................................................3 
1.2.3 The role of hepatic gluconeogenesis in glucose homeostasis ....................5 
1.3 Obesity-associated inflammation and insulin resistance............................6 
1.3.1 IL-6 and insulin resistance ..........................................................................7 
1.3.2 TNF-α and insulin resistance ......................................................................9 
1.4 Cancer and hepatocellular carcinoma (HCC)..............................................10 
1.5 Linking inflammatory processes to HCC.....................................................11 
1.5.1 Toll-like receptor (TLR) signaling in liver damage and HCC.....................11 
1.5.2 MyD88 dependent TLR signaling..............................................................13 
1.5.3 MAPK signaling and HCC.........................................................................14 
1.5.4 NF-κB signaling and HCC.........................................................................15 
1.6 Objectives.......................................................................................................16 
 
2. Materials and Methods: ........................................................................... 17 
2.1 Chemicals and enzymes ...............................................................................17 
2.2 Mouse experiments .......................................................................................21 
2.2.1 Animal care ...............................................................................................21 
2.2.2 Generation of IL-6RαL-KO and MyD88L-KO mice..........................................22 
2.2.3 Body weight and body composition ..........................................................22 
2.2.4 Collection of blood samples and determination of blood glucose levels...22 
2.2.5 Glucose and insulin tolerance test ............................................................23 
Table of contents 
____________________________________________________________________________________________________________________________ 
 II 
2.2.6 Indirect calorimetry, locomoter activity and daily food intake....................23 
2.2.7 Euglycemic-hyperinsulinemic clamp studies (EHCS) ...............................24 
2.2.7.1 Implantation of the catheter ............................................................................24 
2.2.7.2 Radioactive EHCS procedure ........................................................................24 
2.2.7.3 Determination of the glucose turnover rate (mg/[kg*min])..............................25 
2.2.7.4 Calculation of the hepatic glucose production (HGP).....................................26 
2.2.7.5 Determination of the in vivo glucose uptake in the tissues.............................26 
2.2.8 Ablation of Kupffer cells (KCs) ..................................................................26 
2.2.9 Glucose-induced insulin secretion of isolated pancreatic islets ................27 
2.2.10 Diethylnitrosamine (DEN) treatment .......................................................27 
2.2.10.1 Long-term treatment: ....................................................................................27 
2.2.10.2 Short-term treatment: ...................................................................................28 
2.2.11 Analysis of serum protein and cytokine concentrations ..........................28 
2.3 Molecular biology ..........................................................................................29 
2.3.1 Isolation of genomic DNA..........................................................................29 
2.3.2 Quantification of nucleic acids...................................................................29 
2.3.3 Southern blot analysis...............................................................................29 
2.3.4 Polymerase chain reaction (PCR).............................................................30 
2.3.5 RNA extraction ..........................................................................................31 
2.3.6 Quantitative real-time PCR .......................................................................32 
2.4 Biochemistry ..................................................................................................34 
2.4.1 Protein extraction ......................................................................................34 
2.4.2 Western blot analysis ................................................................................35 
2.4.3 Electrophoretic mobility shift assay (EMSA) .............................................36 
2.4.4 Enzyme-linked immunosorbent assay (ELISA).........................................36 
2.4.5 Histological analysis and immunohistochemistry ......................................37 
2.4.5.1 Immunohistochemistry ...................................................................................37 
2.5 Computer analysis.........................................................................................38 
2.5.1 Densitometrical analysis ...........................................................................38 
2.5.2 Quantitation of pancreatic islet mass ........................................................38 
2.5.3 Statistical methods....................................................................................38 
 
3. Results ...................................................................................................... 39 
3.1 The effect of hepatic IL-6Rα  signal transduction on glucose homeostasis
...............................................................................................................................39 
3.1.1 Generation of hepatocyte specific IL-6Rα knock out mice........................39 
Table of contents 
____________________________________________________________________________________________________________________________ 
 III 
3.1.2 IL-6RαL-KO mice exhibit unaltered energy homeostasis ............................41 
3.1.3 IL-6RαL-KO mice exhibit impaired glucose homeostasis and insulin 
sensitivity............................................................................................................44 
3.1.4 IL-6RαL-KO mice exhibit counteracting actions on hepatic glucose 
metabolism.........................................................................................................46 
3.1.5 Mice lacking hepatic IL-6 signaling exhibit insulin resistance in skeletal 
muscle and WAT................................................................................................50 
3.1.6 Increased inflammatory tone in IL-6RαL-KO mice.......................................52 
3.1.7 Neutralization of TNF-α normalizes glucose homeostasis in IL-6RαL-KO 
mice....................................................................................................................56 
3.2 The effect of hepatic Myd88 signaltransduction on glucose homeostasis 
and HCC development.........................................................................................60 
3.2.1 Generation of MyD88L-KO mice ..................................................................60 
3.2.2 Unaltered adiposity in mice lacking hepatic MyD88 signaling ..................62 
3.2.3 Glucose homeostasis and insulin sensitivity is unaltered in MyD88L-KO 
mice....................................................................................................................64 
3.2.4 MyD88L-KO mice exhibit reduced DEN-induced hepatocarcinogenesis .....65 
3.2.5 Reduced expression of macrophage markers in HCC of mice lacking 
hepatic MyD88 signaling ....................................................................................69 
3.2.6 The mRNA expression of LIF in HCC is mediated by hepatic MyD88......71 
3.2.7 Reduced NF-κB activation in DEN-induced HCC of MyD88L-KO mice .......74 
3.2.8 MyD88L-KO mice exhibit reduced hepatic JNK activation in DEN-induced 
HCC ...................................................................................................................75 
 
4. Discussion................................................................................................ 80 
4.1 The ALFP-Cre transgene mediates specific inactivation of the 
loxP-flanked IL-6Rα  or MyD88 alleles in hepatocytes......................................81 
4.2 Hepatocyte specific disruption of the IL-6Rα  impairs glucose 
homeostasis and insulin sensitivity ..................................................................82 
4.3 Crosstalk between hepatocytes and Kupffer cells through hepatic IL-6 
signaling controls the inflammatory tone .........................................................84 
4.5 The role of hepatic MyD88 in energy homeostasis ....................................86 
4.6 Hepatocyte specific disruption of MyD88 reduces chemically induced 
HCC .......................................................................................................................87 
 
Table of contents 
____________________________________________________________________________________________________________________________ 
 IV 
5. Summary................................................................................................... 90 
6. Zusammenfassung .................................................................................. 92 
7. References................................................................................................ 94 
8. Acknowledgements ............................................................................... 113 
9. Erklärung ................................................................................................ 114 
10. Curriculum Vitae .................................................................................. 115 
 
 
 
Figure index 
____________________________________________________________________________________________________________________________ 
 V 
Figure index: 
 
Fig. 1: Prevalence of obesity in adults from 2001 and 2010 .....................................................1 
Fig. 2: Insulin signal transduction ..............................................................................................4 
Fig. 3: The role of G6Pase and GK in the regulation of glucose homeostasis..........................5 
Fig. 4: IL-6 signaling cascade....................................................................................................8 
Fig. 5: Potential mechanisms for the inhibition of insulin signal transduction............................9 
Fig. 6: Cancer distibution and HCC incidence rates worldwide in 2011..................................10 
Fig. 7: Toll-like receptors and their PAMP ligands ..................................................................12 
Fig. 8: Toll-like receptor signaling cascade .............................................................................13 
Fig. 9: Targeting strategy and confirmation of the IL-6RαFL/FL allele .......................................40 
Fig. 10: Liver specific ablation of the IL-6Rα gene..................................................................41 
Fig. 11: IL-6RαL-KO mice show unaltered adiposity..................................................................42 
Fig. 12: Unchanged energy homeostasis in mice lacking hepatic IL-6Rα signaling ...............43 
Fig. 13: IL-6RαL-KO mice exhibit decreased glucose tolerance................................................44 
Fig. 14: Impaired insulin sensitivity in IL-6RαL-KO mice............................................................45 
Fig. 15: Altered regulation of glucose homeostasis in IL-6RαL-KO mice...................................47 
Fig. 16: Counteracting actions on hepatic glucose metabolism in IL-6RαL-KO mice.................49 
Fig. 17: Decreased insulin sensitivity in liver, skeletal muscle and WAT of IL-6RαL-KO mice ..51 
Fig. 18: Increased inflammation in livers of IL-6RαL-KO mice...................................................53 
Fig. 19: IL-6RαL-KO mice exhibit elevated inflammatory state in skeletal muscle.....................54 
Fig. 20: IL-6RαL-KO mice exhibit enhanced systemic inflammation ..........................................55 
Fig. 21: Ablation of TNF-α lead to normalized glucose homeostasis in IL-6RαL-KO mice ........56 
Fig. 22: Normalized glucose homeostasis in IL-6RαL-KO mice after depletion of Kupffer cells 
 ........................................................................................................................................57 
Fig. 23: Alterations of glucose stimulated insulin secretion after depletion of Kupffer cells in 
IL-6RαL-KO mice...............................................................................................................58 
Fig. 24: Targeting strategy and ablation of MyD88 specific in the liver ...................................61 
Fig. 25: Similar bodyweight and body fat content between control and MyD88L-KO mice........63 
Fig. 26: Unaltered cholesterol and lipid metabolism in MyD88L-KO mice .................................63 
Fig. 27: Unaltered glucose homeostasis and insulin sensitivity in MyD88L-KO mice ................65 
Fig. 28: Reduced DEN-induced liver damage in MyD88L-KO mice...........................................67 
Fig. 29: Lower DEN-induced HCC incidence in MyD88L-KO mice ............................................68 
Fig. 30: MyD88L-KO mice show reduced macrophage marker expression in the liver..............70 
Fig. 31: Unaltered mRNA expression of chemokines between control and MyD88L-KO mice ..71 
Fig. 32: Elevated mRNA expression of LIF in MyD88L-KO mice compared to control mice......72 
Fig. 33: Unaltered IL-6 signaling in MyD88L-KO mice compared to control mice upon acute 
DEN treatment ................................................................................................................73 
Figure index 
____________________________________________________________________________________________________________________________ 
 VI 
 
Fig. 34: MyD88L-KO mice exhibit reduced p65 activation upon DEN treatment........................74 
Fig. 35: Reduced JNK activation in HCC of MyD88L-KO mice compared to control mice.........76 
Fig. 36: Unaltered MAPK signaling in MyD88L-KO mice upon acute DEN treatment................77 
Fig. 37: MyD88L-KO mice exhibit decreased pro-apoptotic marker expression ........................78 
 
 
 
Table index 
____________________________________________________________________________________________________________________________ 
 VII 
Table index: 
 
Table 1: Chemicals..................................................................................................................17 
Table 2: Enzymes....................................................................................................................21 
Table 3: List of oligonucleotides used for Southern probe generation ....................................30 
Table 4: List of oligonucleotides used for PCR .......................................................................31 
Table 5: List of Taqman gene expression assays ...................................................................32 
Table 6: List of primary antibodies used for Western blot analysis .........................................35 
Table 7: EMSA probes ............................................................................................................36 
Table 8: List of ELISA kits .......................................................................................................37 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 VIII 
Abbreviations: 
 
°C Degrees celsius 
β-me β-mercaptoethanol 
2DG 2-Deoxy-D-[1-14C] glucose  
2DG6P 2-Deoxy-D-[1-14C] glucose-6-phosphate  
3’ Three prime end of DNA sequences 
5’ Five prime end of DNA sequences 
A Adenosine 
AKT Protein kinase B 
ALFP Albumin promotor/α-fetoprotein enhancer 
ALT Alanine transaminase  
AMP Adenosinmonophosphat 
AMPK AMP-dependent kinase 
AP-1 Activator protein 1 
APS Ammonium persulfate 
ASR Age-standardized incidence rates 
AST Aspartate transaminase  
Ba(OH)2  Barium hydroxide 
Bcl-2 B-cell lymphoma 2 
BHI BamHI 
bp Base pairs 
BMI Body mass index 
BSA Bovine serum albumine 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 IX 
C Cytosine 
c-Jun Jun proto-oncogene 
c-Rel V-rel reticuloendotheliosis viral oncogene homolog (avian) 
CaCl2 Calcium chloride 
CBA Cytometric bead array  
CD-68 Cluster of differentiation 68 
cDNA Complementary DNA 
Ci Curie 
CNS Central nervous system 
CO2 Carbon dioxide 
cps Counts per second 
Cre Site-specific recombinase from phage P1 (causes recombination) 
ct Threshold cycle value  
CTP Cytosine triphosphate 
DAMPS Damage-associated molecular patterns  
DAPI 4',6-diamidino-2-phenylindole 
DEN Diethylnitrosamine 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DNase Desoxyribonuclease 
dNTP Desoxyribonucleotide-triphosphate 
dpm Disintegrations per minute 
ds Double-stranded 
DTT 1,4-Dithio-DL-threitol 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 X 
e.g. exempli gratia 
ECL Enhanced chemiluminescence 
EDTA Ethylendiamine tetraacetate  
EHCS Euglycemic-hyperinsulinemic clamp studies  
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular signal-regulated kinase 
EtBr Ethidium bromide 
EtOH Ethanol 
F4/80 EGF-like module containing, mucin-like, hormone receptor-like sequence 1 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
g Gram 
G Guanine 
G6P Glucose-6-phosphate 
G6Pase  Glucose-6-phosphatase  
GIR Glucose infusion rate 
GK Glucokinase 
Grb2 Growth factor receptor-bound-2 protein 
GSIS Glucose stimulated insulin secretion 
GTP Guanosine triphosphate 
GTT Glucose tolerance test 
Gusb Glucuronidase beta 
h Hour 
H2O Water 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XI 
HCC Hepatocellular carcinoma 
HCl Hydrochloric acid 
H&E Hematoxylin/eosin 
HEPES N-2-hydroxyethylpiperazine-N’-2-ethansulfonic acid 
HGP Hepatic glucose production 
HFD High fat diet 
HMGB1 High mobility group box 1 
HPRT-1 Hypoxanthine guanine phosphoribosyl transferase-1 
i.e. id est 
i.p. Intraperetoneal 
i.v. Intravenous 
IκB Inhibitor of κB  
IKK IκB kinase 
IL-10 Interleukin 10 
IL-1Ra IL-1 receptor antagonist 
IL-6 Interleukin 6 
IL-6Rα Interleukin 6 receptor α 
IR Insulin receptor 
IRAK Interleukin-1 receptor-associated kinase  
IRS Insulin receptor substrate 
ITGAM Integrin-α-M  
ITGAX Integrin-α-X  
ITT Insulin tolerance test 
JNK C-Jun-N-terminal kinase 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XII 
k Kilo 
kb Kilobase  
KC Kupffer cell 
KCl Potassium chloride 
KOH Potassium hydroxide 
l Liter 
LIF Leukemia inhibitory factor 
loxP Recognition sequence for Cre (locus of crossing over phage P1) 
LPS Lipopolysaccharide 
m Milli 
M Mol 
MAC-2 Galectin-3 
MAPK Mitogen-activated protein kinase 
MCP-1 Monocyte chemo-attractant protein 1  
MCP-3 Monocyte chemo-attractant protein 3  
MgCl2 Magnesium chloride 
min Minute 
MIP-1α Macrophage inflammatory protein 1α 
MIP-1β Macrophage inflammatory protein 1β 
MKK MAPK kinase  
MKKK MAPK kinase kinase  
MyD88 Myeloid differentiation primary response gene 88 
mRNA Messenger ribonucleic acid 
NaCl Sodium chloride 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XIII 
n Nano 
NaF Sodium fluoride 
NaOH Sodium hydroxide 
NCD Normal chow diet 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NMR Nuclear magnetic resonance 
O2 Oxygen 
OD Optical density 
P Phosphorylation 
p Pico 
p38 Mitogen-activated protein kinase 14 
p53 Tumor protein p53 
PAGE Polyacrylamid gel electrophoresis 
PAMPS Pathogen-associated patterns 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDK1 Phosphoinositide-dependent protein kinase 1 
PEPCK Phosphoenolpyruvate carboxykinase 
PFA Paraformaldehyde  
PH Pleckstrin homology  
PI3K Phosphatidylinositol 3 kinase 
PIP2  Phosphatidylinositol-4,5-bisphosphate 
PIP3  Phosphatidylinositol-3,4,5-trisphosphate 
PKB Protein kinase B 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XIV 
PMSF Phenylmethylsulfonylfluoride 
PTB Phosphotyrosine binding 
PVDF Polyvinylidene fluoride 
RI EcoRI 
RANTES Regulated upon activation, normally T-expressed, and presumably secreted 
Ras Rat sarcoma 
RD Glucose disposal rate 
RelA V-rel reticuloendotheliosis viral oncogene homolog A 
RelB V-rel reticuloendotheliosis viral oncogene homolog B 
RER Respiratory exchange ratio 
RIP1 Receptor interacting protein 1 
RNA Ribonucleic acid 
RNase Ribonuclease 
ROS Reactive oxygen species 
rpm Rounds per minute 
RT   Room temperature 
SAPK Stress-activated protein kinases 
SDS  Sodiumdodecylsulfate  
sec Second 
SEM Standard error of the mean 
Ser Serin 
SH2 Src-homology 2 
SHP2 SH2-domain-containing phosphatase 
SOCS3 Suppressor of cytokine signalling 3 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XV 
SOS Son of sevenless homolog 
Src Sarcoma 
ss Single-stranded 
SSC Sodium chloride/ sodium citrate buffer 
STAT-3 Signal transducer and activator of transcription 3 
T Thymine 
TAE Tris-acetic acid-EDTA buffer 
Taq Pol Polymerase from Thermus aquaticus 
TBE Tris/borate/EDTA buffer 
TBK1 TANK-binding kinase 1 
TBS Tris buffered saline 
TE Tris-EDTA buffer 
TEMED Tetramethylethylenediamine 
TG Triglyceride 
Thr Threonine 
TIR Toll/interleukin-1 receptor 
TIRAP TIR domain-containing adapter protein 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TNFsRp55 Soluble TNF receptor p55  
TRAF6 Tumor necrosis factor receptor-associated factor 6 
TRAM TRIF-related adapter molecule 
TRIF TIR domain–containing adapter–inducing IFNβ 
Tris 2-amino-2-(hydroxymethyl-)1,3-propandiol 
Abbreviations 
____________________________________________________________________________________________________________________________ 
 XVI 
TWEEN Polyoxethylene-sorbitan-monolaureate 
Tyr Tyrosine 
U Unit 
UV Ultraviolet 
V Volt 
v/v Volume per volume 
W Watt 
w/o Without 
w/v Weight per volume 
WHO World Health Organization 
wt Wild-type 
ZnSO4 Zinc sulfate 
µ Micro 
 
 
 
 
 
 
 
 
 
Introduction 
____________________________________________________________________________________________________________________________ 
 1 
1. Introduction: 
 
1.1 Obesity 
 
Obesity is defined as a condition of abnormal or excessive bodyfat 
accumulation that may have adverse effects on health. It is one of the biggest 
public health threats of the 21st century and its prevalence is steadily 
increasing woldwide (Fig. 1). In 2008, approximately 1.5 billion adults were 
overweight. Of these adults, over 200 million men and approximately 300 
million women were obese. Following recordings of each country in the WHO 
European Region from 2008, over 50% of both men and women have a body 
mass index (BMI = weight in kilograms / size in meters2) higher than 25 and 
are thus considered overweight. Nearly 23% of these were obese indicated by 
a BMI above 30 (1).  
 
Fig. 1: Prevalence of obesity in adults from 2001 and 2010 
The worldwide prevalence of obese adults (BMI >30) compared from 2001 and 2010. Datas 
were obtained from the WHO. 
 
Obesity is known to increase the risk of developing various diseases, such as 
cardiovascular diseases, diabetes mellitus, atherosclerosis and certain types 
of cancer (2-5). As a consequence, approximately 0.7% to 2.8% of a country's 
total healthcare expenditures are associated with overweight and obesity and 
thus place a significant financial burden on the healthcare system (6, 7). Due 
to these facts, remarkable efforts have been conducted to understand the 
regulatory mechanisms of energy homeostasis, insulin action and body weight 
gain. 
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1.2 Energy homeostasis 
 
The relationship between daily energy expenditure and bodyweight regulation 
was first demonstrated 50 years ago (8). To maintain stable body mass and 
body composition, the balance between energy intake and energy 
expenditure is essential and tightly regulated by physiological signals within 
the organism (9-14). These signals include fat mass gain during 
overabundance or increased calorie intake in case of depleted energy (9, 15). 
Malfunction of the regulatory system, either due to genetic predisposition or 
environmental factors or a combination of both, are presumably leading to the 
development of obesity (16-18). Importantly, almost unlimited access to high 
caloric food and the trend to reduced physical activity in industrialized 
countries results in a positive energy balance, ultimately leading to overweight 
and obesity. 
 
In the last decade, numerous studies investigated the underlying regulatory 
mechanisms of energy homeostasis and identified the metabolic hormones 
insulin and leptin as two of the central regulators of body weight control, 
energy homeostasis and glucose metabolism (19, 20).  
 
 
1.2.1 The role of insulin signaling in energy homeostasis 
 
The peptide hormone insulin is secreted by β-cells, which are exclusively 
located on the pancreatic islets of Langerhans. Its active form is derived from 
cleavage of the inactive precursor proinsulin in the β-cells (21). As response 
to rising blood glucose levels, insulin is released into the circulation, and 
subsequently stimulates glucose uptake in peripheral tissues (22, 23). After 
being taken up into the cell, glucose is either directly metabolized to generate 
energy in the form of adenosine-5'-triphosphate (ATP) or, especially in liver 
and muscle, stored as glycogen. Furthermore, insulin is also involved in the 
control of different metabolic processes, such as the stimulation of amino acid 
uptake and glycolysis, as well as the inhibition of catabolic processes, such as 
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glycogenolysis, gluconeogenesis and hepatic glucose production (24, 25). 
The amino acid sequence of insulin is highly conserved among vertebrates 
and some other species, emphasizing the importance of this hormone and its 
pleiotropic effects (26). 
 
 
1.2.2 The insulin signaling cascade 
 
Upon release, insulin binds to its receptor and initiates an intracellular 
signaling cascade (Fig. 2) resulting in the regulation of various cellular 
functions (27). Like other receptors for protein hormones, the insulin receptor 
(IR) is a membrane-bound receptor and belongs to the family of receptor 
tyrosine kinases. The IR comprises two extracellular α- and two intracellular 
β-subunits, which are linked by disulfide bridges. Binding of insulin to the 
α-subunits induces a conformational change of the receptor, leading to the 
activation of the intrinsic tyrosine kinase activity of the β-subunits and thus to 
autophosphorylation of multiple tyrosine residues (28-30). Due to these 
phosphorylations, intracellular signaling molecules, such as the four closely 
related insulin receptor substrates (IRS 1-4) are recruited to the IR via the 
phospho-tyrosine binding (PTB) domain, resulting in their activation by 
tyrosine phosphorylation (31, 32). Additionally, most of the IRS proteins 
contain a N-terminal pleckstrin homology (PH) domain, allowing the 
localization of the IR and its downstream targets to the membrane by 
interactions with inositol phosphates in the cell membrane (33, 34). After 
activation and localization to the membrane, the IRS proteins serve as 
docking platforms for proteins containing a rous sarcoma virus 
(Src)-homology 2 (SH2) domain. Different signaling molecules, such as 
growth factor receptor-bound-2 protein (Grb2), the protein tyrosine 
phosphatase 2 (Shp2) and the regulatory subunit p85 of phosphatidylinositol 
3 kinase (PI3K), contain a SH2 domain and interact with IRS proteins (35-38). 
Whereas Grb2 subsequently mediates activation of the mitogen activated 
protein kinase (MAPK) pathway, responsible for regulating cell growth and 
mitosis (39), PI3K activation mediates the majority of insulin’s effects on 
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glucose and lipid metabolism (40-42). The PI3K primarily catalyzes the 
phosphorylation of phosphatidylinositol (4,5) bisphophate (PIP2) to 
phosphatidylinositol (3,4,5) trisphosphate (PIP3). PIP3 in turn translocates the 
protein kinase B (PKB, also known as AKT), co-localized with the 
phosphoinositide-dependent protein kinase 1 (PDK1), to the cell membrane 
and leading to the activation of AKT (43, 44). AKT then regulates the 
activation of downstream targets (45). 
Fig. 2: Insulin signal transduction 
Binding of insulin to the insulin receptor results in a conformational change of the receptor 
and autophosphorylation of the intracellular β-subunits. This leads to recruitment and 
activation of IRS proteins, which in turn serve as docking platforms for other SH2 domain 
containing proteins, e.g. Grb2 or PI3K. Activation of these proteins subsequently drives 
further downstream signaling pathways, such as MAPK or AKT, responsible for growth and 
glucose homeostasis. 
 
Resistance to the metabolic effects of insulin represents one of the major 
consequences of excessive weight gain and obesity. It is characterized by a 
reduced ability of insulin to activate its downstream signaling cascade, thus 
leading to disturbed glucose clearance from the blood. 
 
 
 
 
 
Introduction 
____________________________________________________________________________________________________________________________ 
 5 
1.2.3 The role of hepatic gluconeogenesis in glucose homeostasis 
 
One of the most strictly controlled processes in energy homeostasis is the 
maintainance of steady blood glucose levels. In response to a high blood 
glucose concentration, insulin is released and promotes hepatic glucose 
storage in form of glycogen. Conversely, if blood glucose levels drop, 
catabolic pathways promote the breakdown of glycogen to glucose and its 
subsequent release into the bloodstream. Since the generation of glucose 
from glycogen is rather short-lived, long-term energy supply, e.g. during long 
fasting periods, is highly dependent on hepatic gluconeogenesis (46-48). 
Therefore, hepatic gluconeogenesis is of central importance to maintain 
constant blood glucose levels (49). Notably, obesity-associated insulin 
resistance and subsequent hyperglycemia is thought to arise, at least 
partially, from a deregulation of hepatic glucose production due to the reduced 
ability of insulin to inhibit gluconeogenesis (50-53).  
 
During gluconeogenesis, glucose is generated from non-carbohydrate 
substrates in a cascade of enzymatic reactions. Rate-limiting enzymes, such 
as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate 
carboxykinase (PEPCK), control important nodes of this pathway and 
therefore can adjust its activity in response to hormonal stimuli, e.g. insulin or 
glucagon (Fig. 3) (54, 55).  
 
Fig. 3: The role of G6Pase and GK in the regulation of glucose homeostasis 
Insulin is released in response to high blood glucose level, which stimulates glucose uptake in 
peripheral tissues. There, glucokinase catalyzes the phosphorylation of glucose into G6P, 
which is used for glycogenesis or glycolysis. On the other hand, gluconeogenesis generates 
glucose from non-carbohydrate substrates by synthesis of G6P. As a rate-limiting enzyme, 
G6Pase is required for the convertion of glucose-6-phosphate into glucose, which is  
then released into the bloodstream. 
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G6Pase is required for the conversion of glucose-6-phosphate (G6P) into 
glucose, and its inactivation or inhibition leads to poor fasting tolerance, 
accumulation of glycogen in the liver and ultimately to metabolic disorders 
(56). In contrast, the insulin-regulated glucokinase (GK) acts antagonistically 
to G6Pase by catalyzing the phosphorylation of glucose to produce G6P, thus 
preventing glucose to be released from the cell (Fig. 3) (57-59). After 
phosphorylation to G6P, glucose is able to enter the glycolysis or 
glycogenesis. 
 
In summary, hepatic glucose output is regulated by the rates of hepatic 
glucose production (HGP) and hepatic glucose utilization. Thus, 
glycogenolysis, gluconeogenesis, and glucose cycling between glucose and 
G6P are important mechanisms in regulating glucose homeostasis. 
 
 
1.3 Obesity-associated inflammation and insulin resistance 
 
The concept of chronic, low level inflammation in response to obesity was first 
shown by markedly increased expression of the pro-inflammatory cytokine 
tumor necrosis factor α (TNF-α) in adipose tissue of obese rodents. 
Administration of a recombinant soluble TNF-α receptor (TNFR) 
immunoglobulin neutralized TNF-α in these rodents and ameliorates insulin 
sensitivity (60). Thus, the first link between an increase in pro-inflammatory 
cytokines and insulin resistance was established. Follow-up studies confirmed 
this observation in humans, where adipose tissue also increasingly expressed 
TNF-α upon obesity, which was decreased after weight loss, together with a 
restoration of insulin sensitivity (61-64). Additional work demonstrated that 
obesity is associated with a state of chronic, low-grade inflammation not only 
locally in adipose tissue, but also systemically, indicated by elevated plasma 
concentrations of other inflammation-associated factors despite TNF-α, such 
as interleukin-6 (IL-6) and interleukin-10 (IL-10) (65-68). During the 
development of obesity, immune cells, e.g. macrophages, infiltrate tissues, 
such as white adipose tissue (WAT) and lead to increased secretion of TNF-α 
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and IL-6 (69, 70). Furthermore, chronic inflammation in WAT, liver and 
skeletal muscle plays a crucial role in the development of obesity-induced 
insulin resistance (69, 71, 72). In the liver, Kupffer cells (KC) represent the 
population of resident macrophages, which are derived from circulating 
monocytes and line the sinusoid walls of the liver (73, 74). They are thought to 
be the main source of hepatic TNF-α, although other local types of cells are 
also able to produce this pro-inflammatory cytokine.  
 
 
1.3.1 IL-6 and insulin resistance 
 
IL-6 is a pleiotropic cytokine that not only affects the immune system, but also 
drives many physiological events in various tissues. Binding of IL-6 to its 
receptor complex, comprising of IL-6Rα and gp130, leads to the 
phosphorylation of the Janus kinase (JAK) and subsequent phosphorylation of 
the receptor complex. This phosphorylation interacts with proteins harbouring 
a SH2 domain. Signal transducer and activator of transcription (STAT) and  
tyrosine-protein phosphatase non-receptor type 11 (SHP-2) contain SH2 
domains and are capable of binding to the receptors, resulting in the 
phosphorylation of specific tyrosine residues by JAK. Activated STATs form 
dimers and activate transcription of their target genes, such as suppressor of 
cytokine signaling 3 (SOCS-3) (75).  An alternative IL-6 signaling branch 
results in the phosphorylation of SHP-2 that leads to rat sarcoma 
(ras)-mediated activation of mitogen-activated protein kinase (MAPK) 
signaling (Fig. 4) (76).  
 
Currently, the function of IL-6 as mediator of obesity-induced insulin 
resistance is controversially discussed (77). Due to the observation that IL-6, 
along with the pro-inflammatory cytokine TNF-α, is often elevated in serum 
during obesity or in patients with metabolic diseases, it has been suggested 
that IL-6 signaling promotes insulin resistance (78, 79). Consistently, IL-6 
treatment induces cellular insulin resistance in hepatocytes and injection of 
IL-6 triggers expression of suppressor of cytokine signaling 3 (SOCS-3), 
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which can potentially inhibit insulin action (80, 81). Moreover, IL-6 infusion 
during euglycemic-hyperinsulinemic clamp studies markedly blunts insulin 
response, reflected by a lower glucose infusion rate, indicating that IL-6 
indeed causes insulin resistance (82). 
 
Fig. 4: IL-6 signaling cascade 
Binding of IL-6 to its receptor complex, comprising of IL-6Rα and gp130, leads to the 
phosphorylation of JAK and subsequent phosphorylation of the receptor complex. 
Recruitment of STAT-3 or SHP-2 to the receptor leads to their activation by phosphorylation 
through JAK. Active STAT-3 forms dimers, whereas SHP-2 leads first to the activation of 
ERK, which in turn dimerize. These dimers then translocate into the nucleus and activate the 
transcription of target genes. 
 
Whereas these studies suggest a harmful role of IL-6 action in the 
development of obesity-associated insulin resistance, other reports could 
demonstrate a positive effect of IL-6 on glucose metabolism. Acute treatment 
with IL-6 increases insulin-stimulated glucose disposal rate in healthy 
humans, without affecting endogenous glucose production, by an 
AMP-dependent kinase (AMPK) mediated mechanism (83). Additional 
findings reveal that IL-6 injection increases systemic insulin sensitivity and 
improves glucose tolerance (84). A connection between insulin action in the 
central nervous system (CNS) and hepatic IL-6 release was also shown. 
Following activation of signal transducer and activator of transcription 
(STAT-3) in hepatocytes (Fig. 4) leads to inhibition of G6Pase and PEPCK 
expression (85). 
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1.3.2 TNF-α and insulin resistance 
 
The role of TNF-α in developing obesity-associated insulin resistance is 
object of many observations and an increased expression of TNF-α in skeletal 
muscle from insulin-resistant humans has also been noted (86). Additionally, 
prolonged infusion of TNF-α impairs insulin-mediated glucose disposal and 
insulin-stimulated suppression of total hepatic glucose output, whereas HGP 
and glucose utilization were elevated (87).  
 
 
Fig. 5: Potential mechanisms for the inhibition of insulin signal transduction 
Activation of cell surface receptors, which induce serine kinases, such as c-Jun N-terminal 
kinase (JNK) and inhibitor of NF-κB kinase (IKK) complex, mediate inhibitory serine (S307) 
phosphorylation events on insulin receptor substrates (IRS) and thereby blocking insulin 
action. Furthermore, endoplasmatic reticulum (ER) stress and intermediates of fatty acid 
metabolism may activate stress kinases.  
 
It was also shown that inhibition of TNF-α improves hepatic and peripheral 
insulin sensitivity in vivo (88). Finally, activation of TNF-α downstream kinases 
(Fig. 5), such as inhibitor of nuclear factor κB (NF-κB) kinases (IKK) and 
c-Jun amino-terminal kinases (JNK), reveal impaired insulin signal 
transduction in peripheral tissues (71, 89-91). 
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1.4 Cancer and hepatocellular carcinoma (HCC) 
 
Cancer is a generic term for a large group of diseases that can occur in 
alomost all parts of the body. It is characterized by an uncontrolled cell growth 
that leads to tumor formation and invasion of these cells into nearby tissues 
(92). The surrounding tissue is often destroyed by the cancer growth and 
invasion. Influenced by an increasing and aging population, the World Health 
Organization (WHO) estimates that the global cancer-related mortality rate will 
increase from 7.9 million (2007) to 11.5 million (2030) incidents per year. The 
WHO also suggests that the majority of all cancer cases occurs in low- and 
middle-income countries, such as Asia and South America. Nevertheless, in 
most industrialized countries, cancer is the second most frequent cause of 
death after cardiovascular diseases (93). 
 
Hepatocellular carcinoma (HCC) represents approximately 85%-90% of 
primary liver cancers (94), with an average mortality of 95% within 5 years. 
Since it often remains unnoticed in the early stages, HCC is usually advanced 
when the patients exhibit clinical symptoms. Due to this fact, it represents the 
third largest cause of cancer deaths worldwide, particularly in Africa and 
Eastern Asia (Fig. 6). However, the incidence of HCC in Western countries 
cannot be ignored, as it is rising constantly (95).  
 
Fig. 6: Cancer distibution and HCC incidence rates worldwide in 2011 
(A) Worldwide distribution of different cancer forms of both genders in percentage of total 
cancer numbers from 2011. (B) Distribution of HCC incidence in 2011 (ASR per 100000). 
Data from (A) and (B) are documented by the WHO globocan project. 
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A variety of genetic predispositions, such as mutations in tumor suppressor 
genes, are linked to HCC, as well as cirrhosis which is caused by chronic 
hepatitis infections, alcohol abuse or metabolic disorders, e.g. due to obesity 
(96-102). Strikingly, male individuals have a 4 times higher risk to develop 
liver cancer than women. 
 
 
1.5 Linking inflammatory processes to HCC 
 
The observation that leukocytes are highly abundant in neoplastic tissue was 
the first indicator for a connection between inflammation and cancer (103). 
Over the last decades, several reports raised the hypothesis of 
inflammation-mediated oncogenesis (104). HCC represents a classic case of 
inflammation-associated cancer, since it is promoted by chronic hepatic 
inflammation due to hepatic injury (105, 106). A response mechanism to this 
chronic inflammation is the compensatory proliferation of hepatocytes, which 
may ultimately lead to HCC (107).  
 
 
1.5.1 Toll-like receptor (TLR) signaling in liver damage and HCC 
 
The toll-like receptor (TLR) signaling pathway represents a classic signaling 
cascade in innate immune cells and its activation is thought to be linked to the 
development of HCC as result of chronic liver diseases (108). Exogenous 
ligands, such as microbial components, known as pathogen-associated 
molecular patterns (PAMPS), specifically activate their corresponding TLR 
(Fig. 7) (109). Furthermore, endogenous TLR ligands, so called 
damage-associated molecular patterns (DAMPS), are able to trigger TLR 
signaling (110). The majority of these ligands, such as high mobility group box 
1 (HMGB1), heat shock proteins and free fatty acids, are predominantly 
released from dying cells (111-113).  
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Fig. 7: Toll-like receptors and their PAMP ligands 
The family of mammalian TLRs, their microbial component ligands and the used adaptor 
proteins for activation and proper signal transduction. 
 
TLRs are highly dependent on specific adapter molecules and kinases, such 
as myeloid differentiation primary response gene 88 (MyD88), TIR domain-
containing adapter protein (TIRAP),  TIR domain-containing adapter inducing 
interferon-β (TRIF) and TIR domain-containing adapter protein (TRAM) 
(Fig. 7) (114-116). These adaptor molecules activate downstream targets 
upon binding of DAMPS or PAMPS to their corresponding TLRs, which 
ultimately triggers the transcription of cytokines or chemokines, among others 
(117). 
 
Mice deficient in MyD88 are highly resistant to chemically induced HCC (e.g. 
by administration of diethylnitrosamine (DEN)), indicating a strong connection 
between TLR signaling and hepatocarcinogenesis (118). Presumably, DEN 
induces cell death in hepatocytes, which in turn activates KCs via TLRs and 
induces expression of pro-inflammatory cytokines, eventually enhancing the 
development of HCC (119). Although KCs are the initial cells responding to 
PAMPS in the liver, recent studies provide evidence for an active TLR 
signaling cascade in hepatic nonimmune cells, e.g. hepatocytes (120, 121). 
However, MyD88 deficient cells are still able to activate JNK and NF-κB in 
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response to the TLR-4 ligand lipopolysaccharide (LPS), indicating signal 
activation in a MyD88 independent manner (Fig. 8) (122). 
 
 
1.5.2 MyD88 dependent TLR signaling 
 
MyD88 is a central adaptor protein, used by almost all TLRs for intracellular 
signaling (Fig. 7). Upon activation of TLRs by specific stimuli, toll/interleukin-1 
receptor (TIR) domain containing adaptors, such as MyD88 and TIR 
domain-containing adapter protein (TIRAP), interact with the TIR domain of 
TLRs. This association recruits members of the interleukin-1 
receptor-associated kinase (IRAK) family, followed by their phosphorylation 
and dissociation from MyD88. Active IRAKs then associtate with tumor 
necrosis factor receptor-associated factor 6 (TRAF6), leading to the activation 
of two distinct signaling pathways and finally to the activation of JNK and 
NF-κB (Fig. 8) (117). 
 
Fig. 8: Toll-like receptor signaling cascade 
The intracellular TLR-signaling cascade in a MyD88 dependent (right) and independent (left) 
manner. 
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1.5.3 MAPK signaling and HCC 
 
The mammalian family of mitogen-activated protein kinases (MAPKs) consists 
of extracellular signal-regulated kinase (ERK), p38, and JNK, and each of 
these exists in several isoforms. For intact MAPK signaling, the induction of at 
least three kinases is necessary to establish the sequential activation 
pathway, the MAPK kinase kinase (MKKK), MAPK kinase (MKK), and MAPK 
itself. Generally, these signaling components are expressed in all cell types 
and transduce signaling upon stimulation with cytokines, growth factors and 
stress signals (123). Moreover, the MAPK signaling pathways are often 
deregulated in various types of cancers, including HCC (124).  
 
ERK1 and ERK2 are highly homologous and display overlapping regulatory 
mechanisms (125). They are activated by a wide variety of receptors, 
particularly receptor tyrosine kinases. Alterations of the ERK pathway are 
contributed to the development of HCC, especially elevated levels of active 
ERK were observed in hepatocellular carcinomas (126). 
 
The p38 subfamily consists of four different isoforms (p38α, p38β, p38γ and 
p38σ) and their activation is mediated by the upstream kinases MKK3, MKK4, 
and MKK6 (127-131). Published studies about p38 MAPK mostly refer to 
p38α, which is involved in inflammation induced apoptosis as well as various 
types of stresses (132-134). An important role in suppression of HCC 
tumorgenesis has also been demonstrated. Mice lacking hepatic p38α exhibit 
enhanced HCC development, triggered by accumulation of reactive oxygen 
species (ROS), which leads to enhanced liver injury (135). 
 
JNK proteins are encoded by three genes: JNK1, JNK2 and JNK3.  JNK1 and 
JNK2 are ubiquitously expressed, whereas JNK3 is mainly found in brain, 
heart and testis (136, 137). Their regulation is mediated by the upstream 
MAPK kinases, MKK4 and MKK7, which are activated upon stimulation with 
stress signals and pro-inflammatory stimuli (138, 139). During HCC 
development, the JNK pathway was assigned a pro-oncogenic role. Increased 
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JNK1 activity was observed in human HCC and mice lacking JNK1 exhibit 
reduced liver carcinogenesis (140, 141). Additionally, the downstream target 
c-Jun promotes chemically induced liver cancer through suppression of the 
p53 pathway (142). 
 
 
1.5.4 NF-κB signaling and HCC 
 
The mammalian family of NF-κB transcription factors consists of five 
members (RelA, RelB, c-Rel, NF-κB1, and NF-κB2), which are assembled by 
dimerization (143). Among the inflammatory signaling pathways that are 
associated with cancer development, the transcription factor NF-κB is of 
central importance in the promotion of tumor development (144), since it is 
involved in the regulation of immune responses, inflammation and cell survival 
(145). Various pro-inflammatory stimuli are able to activate NF-κB, mainly via 
activation of IKK. IKK in turn phosphorylates IκB proteins, which keep NF-κB 
in an inactive state, leading to the degradation of IκB (146). The most 
prominent IκB protein is IκBα. Since NF-κB is a major activator of 
anti-apoptotic gene expression, it is thought to play a key role in tumorgenesis 
(147, 148). Evidence for the involvement in mouse carcinogenesis in vivo was 
shown by the promotion of inflammation-induced cancer by NF-κB (149-151). 
In contrast, other published studies showed that inactivation of hepatic NF-κB 
increases HCC incidence, indicating a suppressive role in tumor development 
(152, 153).  
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1.6 Objectives 
 
Obesity-associated insulin resistance as well as hepatocellular carcinoma are 
steadily increasing diseases worldwide and both are somehow related with 
inflammation. Additionally, epidemiological studies have shown that obesity is 
a risk factor for hepatocellular carcinoma, indicating related mechanisms in 
the development of both diseases. Understanding the underlying mechanisms 
involved in the development of obesity and hepatocellular carcinoma is a first 
step to find therapeutical approaches to treat this diseases. The liver, affected 
in both, is known to play a key role and is subject of many studies. The aim of 
this study was to analyse inflammatory pathways in the development of 
obesity-associated insulin resistance and chemically induced hepatocellular 
carcinoma in vivo. Therefore, mice with conditional disruption of either the 
IL-6Rα or the TLR adaptor protein MyD88 in hepatocytes were generated. 
Mice lacking hepatic IL-6 signaling served for the analysis of energy 
homeostasis, glucose metabolism and insulin signaling. For the analysis of 
hepatic inflammatory processes in the development of chemically induced 
hepatocellular carcinoma, mice lacking MyD88 in the liver were used. 
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2. Materials and Methods: 
 
2.1 Chemicals and enzymes 
 
Size markers for agarose gel electrophoresis (Gene Ruler DNA ladder mix) 
and for SDS-PAGE (Prestained protein ladder Mix) were got from Fermentas 
(St. Leon-Rot, Germany). For polymerase chain reactions, RedTaq 
polymerase (Sigma-Aldrich, Seelze, Germany) or DreamTaq (Fermentas, St. 
Leon-Rot, Germany) were used. Chemicals and enzymes used in this work 
are listed in table 1 and 2, respectively. All solutions were prepared with 
double distilled water. 
 
Table 1: Chemicals 
Chemical Distributor 
α[32P]-dCTPs Amersham, Freiburg, Germany 
β-Mercaptoethanol (β-ME) AppliChem, Darmstadt, Germany 
γ[32P]-dATP  Amersham, Freiburg, Germany 
ε-Aminocaproic acid Sigma-Aldrich, Seelze, Germany 
0.9% Saline (sterile) Delta Select, Pfullingen, Germany 
2,2,2-Tribromoethanol (Avertin®) Sigma-Aldrich, Seelze, Germany  
2-Deoxy-D-[1-14C]-Glucose Amersham, Freiburg, Germany 
Acetic acid Merck, Darmstadt, Germany  
Acrylamide  Roth, Karlsruhe, Germany 
Agarose  Peqlab, Erlangen, Germany  
Ammonium acetate  Merck, Darmstadt, Germany  
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany  
Aprotinin Sigma-Aldrich, Seelze, Germany 
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Biotin  Bode Chemie, Hamburg, Germany 
Complex-Vectastain Elite  Fluka, Sigma-Aldrich, Seelze, Germany  
Bacillol® Sigma-Aldrich, Seelze, Germany  
Barium hydroxide (Ba(OH)2) Sigma-Aldrich, Seelze, Germany  
Benzamidine Merck, Darmstadt, Germany 
Bovine serum albumin (BSA)  Merck, Darmstadt, Germany  
Bradford reagent Bio-Rad, München, Germany 
Bromphenol blue  Merck, Darmstadt, Germany 
Calcium chloride (CaCl2) AppliChem, Darmstadt, Germany 
Chloroform Sigma-Aldrich, Seelze, Germany 
Count offTM  NEN® Research Products, Boston, USA  
D-[3-3H]-Glucose  Amersham, Freiburg, Germany  
Desoxy-ribonucleotid-triphosphates (dNTPs)  Amersham, Freiburg, Germany  
Dextrane sulfate Sigma-Aldrich, Seelze, Germany 
Dimethylsulfoxide (DMSO)  Merck, Darmstadt, Germany 
Di-sodiumhydrogenphosphate  Merck, Darmstadt, Germany  
Dithiothreitol (DTT) Boehringer, Mannheim, Germany 
Enhanced chemiluminescence (ECL) Kit  Perbio Science, Bonn, Germany  
Ethanol, absolute  AppliChem, Darmstadt, Germany  
Ethidium bromide  Sigma-Aldrich, Seelze, Germany  
Ethylendiamine tetraacetate (EDTA)  AppliChem, Darmstadt, Germany  
Fetal calf serum (FCS) Gibco BRL, Eggenstein, Germany 
Forene® (isoflurane)  Abbot GmbH, Wiesbaden, Germany  
Glucose (20%)  DeltaSelect, Pfullingen, Germany  
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Glutamine Invitrogen, Karlsruhe, Germany 
Glycerol  Serva, Heidelberg, Germany  
Glycine  Applichem, Darmstadt, Germany  
HEPES  Applichem, Darmstadt, Germany  
Hydrochloric acid (37%) (HCl) KMF Laborchemie, Lohmar, Germany  
Hydrogen peroxide  Sigma-Aldrich, Seelze, Germany  
Insulin  Novo Nordisk, Bagsværd, Denmark  
Isopropanol (2-propanol)  Roth, Karlsruhe, Germany  
Magnesium chloride  Merck, Darmstadt, Germany  
Methanol  Roth, Karlsruhe, Germany  
N-Nitrosodiethylamine (DEN) Sigma-Aldrich, Seelze, Germany 
Nitrogen (liquid)  Linde, Pullach, Germany  
NP-40 Merck, Darmstadt, Germany  
Octenisept®  Schülke & Mayr, Norderstedt, Germany  
Paraformaldehyde (PFA)  Fluka, Sigma-Aldrich, Seelze, Germany  
Penicillin/Streptomycin solution Gibco BRL, Eggenstein, Germany 
Phenol-chloroform-isoamyl alcohol AppliChem, Darmstadt, Germany 
Phenylmethylsulfonylfluoride (PMSF)  Sigma-Aldrich, Seelze,  
Phosphate buffered saline (PBS)  Germany Gibco BRL, Eggenstein, Germany  
Poly (dI-dC) Amersham Pharmacia Biotec, Uppsala, Sweden 
Potassium chloride  Merck, Darmstadt, Germany  
Potassium hydroxide  Merck, Darmstadt, Germany  
Protease inhibitor cocktail Roche, Mannheim, Germany 
RPMI 1640 medium Gibco BRL, Eggenstein, Germany 
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Ready SafeTM, liquid scintillation cocktail  Beckman Coulter, Fullerton, USA  
Sodium acetate  AppliChem, Darmstadt, Germany  
Sodium chloride (NaCl) AppliChem, Darmstadt, Germany  
Sodium citrate  Merck, Darmstadt, Germany  
Sodium dodecyl sulfate (SDS) AppliChem, Darmstadt, Germany  
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium heparin (Liquemin®)  Roche, Grenzach-Wyhlen, Switzerland  
Sodium hydroxide (NaOH) AppliChem, Darmstadt, Germany  
Sodium orthovanadate  Sigma-Aldrich, Seelze, Germany  
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, Seelze, Germany 
Tissue freezing medium Jung, Heidelberg, Germany  
Tramadolhydrochlorid (Tramal®)  Grünenthal, Aachen, Germany  
TriFast™ Peqlab, Erlangen, Germany  
Trishydroxymethylaminomethane (Tris)  AppliChem, Darmstadt, Germany  
Triton X-100  Applichem, Darmstadt, Germany  
Tween 20 Applichem, Darmstadt, Germany  
Vectashield® mountin medium with DAPI  Applichem, Darmstadt, Germany 
Western blocking reagent  Vector, Burlingame, USA  
Xylene cyanol Sigma-Aldrich, Seelze, Germany 
Zinc sulfate (ZnSO4) Roche, Mannheim, Germany 
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Table 2: Enzymes 
Enzyme Distributor 
BglI NEB, Schwalbach, Germany 
DNase, RNase-free Promega, Madison, WI, USA 
EuroScript reverse transcriptase Eurogentec, Seraing, Belgium 
Proteinase K Roche, Mannheim, Germany 
RNAseI Fermentas, St. Leon-Rot, Germany 
T4 polynucleotide kinase NEB, Schwalbach, Germany 
 
 
2.2 Mouse experiments 
 
General animal handling was performed as described by Hogan (154) and 
Silver (155). 
 
 
2.2.1 Animal care 
 
Care and procedures of all animals was approved by local government 
authorities (Bezirksregierung Köln, Cologne, Germany) and reviewed by the 
animal care committee of the University of Cologne in accordance with 
National Institutes of Health guidelines. Animals were kept in groups of 3 to 5 
animals (depending on weight) or individually (depending on the experiment). 
Mice were housed at 22°C – 24°C using a 12 h light / 12 h dark cycle with 
lights on at 7 AM. Animals were fed regular chow food (NCD; Teklad Global 
Rodent 2018; Harlan) containing 53.5% carbohydrates, 18.5% protein, and 
5.5% fat (12% of calories from fat) and had ad libitum access to water at all 
times. Food was only withdrawn if required for an experiment. Mice were 
sacrificed at the end of the study period by lethal CO2 anaesthesia, the 
relevant organs were dissected, snap-frozen and stored at -80°C until further 
preparation. 
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2.2.2 Generation of IL-6RαL-KO and MyD88L-KO mice 
 
For the generation of IL-6RαL-KO and MyD88L-KO mice, albumin 
promotor/α-fetoprotein enhancer (ALFP)-Cre+/- mice were mated with either 
MyD88FL/FL or IL-6RαFL/FL mice (generated and kindly provided by PD Dr. F. 
Thomas Wunderlich from the laboratory of Prof. Dr. Jens C. Brüning in the 
Institute for Genetics, University of Cologne, Germany) and double 
heterozygous mice were further intercrossed to yield hepatocyte specific 
IL-6Rα or MyD88 knockout mice (IL-6RαL-KO and MyD88L-KO). 
 
The breeding colonies were maintained by mating either MyD88FL/FL or 
IL-6RαFL/FL mice with ALFP-Cre+/- MyD88FL/FL or ALFP-Cre+/- IL-6RαFL/FL mice, 
respectively. All mice had been backcrossed for 10 generations on a C57BL/6 
background before used for experiments and the background was unchanged 
throughout all experiments. Littermates were used for analysis at all times and 
were genotyped by PCR using genomic DNA isolated from tail tips. 
 
 
2.2.3 Body weight and body composition 
 
Body weight was measured once a week and body composition was 
measured in vivo by nuclear magnetic resonance using the minispec mq 7.5 
(Bruker Optik, Ettlingen, Germany) at the end of the study period. 
 
 
2.2.4 Collection of blood samples and determination of blood glucose levels 
 
The collection of blood samples was performed according to guidelines (154, 
155) in the morning to avoid variations by the circadian rhythm. The blood 
cells and platelets were separated from serum by centrifugation of the blood 
samples for 30 min at 4°C. The obtained serum was stored at -20°C. 
 
Materials and Methods 
____________________________________________________________________________________________________________________________ 
 23 
The determination of blood glucose levels was performed from whole venous 
blood using an automatic glucose monitor (GlucoMen® GlycÓ; A. Menarini 
Diagnostics). 
 
 
2.2.5 Glucose and insulin tolerance test 
 
Glucose tolerance tests (GTT) were performed on animals after a fasting 
period of 16 h over night. Insulin tolerance tests (ITT) were performed on 
random fed mice. The animals received an i.p. injection of either 2 g/kg body 
weight of glucose or 0.75 U/kg body weight of human regular insulin, 
respectively. Glucose levels were determined in blood collected from the tail 
tip immediately before and 15, 30 and 60 min after the injection of insulin, with 
an additional measurement after 120 min for the GTT. 
 
 
2.2.6 Indirect calorimetry, locomoter activity and daily food intake 
 
The measurements for indirect calorimetry, locomoter activity and daily food 
intake over 48 h were performed in 7.1-l chambers of the PhenoMaster 
System (TSE systems, Bad Homburg, Germany) at room temperature 
(22 - 24°C). For the adaptation, the mice were placed in the chambers for 
48 h before the experiment. The food and water were provided ad libitum in 
appropriate devices and daily food intake was measured through the 
PhenoMaster System as well as VO2 and VCO2 by indirect calorimetry. To 
monitor the locomotor activity, an infrared light-beam frame was used. 
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2.2.7 Euglycemic-hyperinsulinemic clamp studies (EHCS) 
 
 
2.2.7.1 Implantation of the catheter 
 
Male mice at the age of 10 weeks were anesthetized by an intraperetoneal 
injection of 240 mg/kg avertin and adequacy of the anesthesia was ensured 
by the loss of pedal reflexes. After the loss of pedal reflexes, a 
Micro-Renathane catheter (Micro-Renathane, MRE 025; Braintree Scientific 
Inc., Braintree, Massachusetts, USA) was inserted into the right internal 
jugular vein and advanced to the level of the superior vena cava. After the 
irrigation with 0.9% saline solution, the catheter was filled with heparin 
solution, sealed at its distal end and left in a subcutaneous pocket at the back 
of the neck. The cutaneous incisions were closed with a 4-0 silk suture and 
the free end of the catheter was attached to the suture in the neck in such a 
fashion as to allow the retrieval of the catheter on the day of the experiment. 
After the implantation of the catheter the mice received an intraperitoneal 
injection of 1 ml saline solution (0.9%) containing 15 µg/g body weight of 
tramadol and were placed on a heating pad in order to facilitate recovery. 
  
 
2.2.7.2 Radioactive EHCS procedure 
 
After 6 days of recovery, only mice that had lost less than 10% of their 
preoperative weight were studied and included in the experimental groups. 
Each animal was fasted for 16 h and placed into restrainers for the whole 
duration of the clamp experiment. After an infusion of a 5 µCi D-[3-3H] glucose 
tracer bolus solution at the beginning of the experiment, a tracer solution 
(0.05 µCi/min) was infused continuously for the whole experiment. At the end 
of the basal period (40 min), a blood sample (60 µl) was collected to 
determine the basal parameters and a 40 µU/g insulin bolus solution was 
infused, followed by the infusion of a 4 µU/g/min insulin solution containing 
0.1% BSA at a fixed rate. To minimize blood loss, red blood cells were 
Materials and Methods 
____________________________________________________________________________________________________________________________ 
 25 
collected by centrifugation and reinfused after being resuspended in 0.9% 
saline solution. The blood glucose levels were analyzed every 10 min with a 
B-Glucose Analyser (Hemocue, Wetzikon, Switzerland). To prevent 
counterregulatory response to hypoglycemia, a 20% glucose solution was 
infused to maintain the physiological blood glucose level (120 - 145 mg/dl). 
Approximately 60 min before the steady state period, a 10 µCi bolus of 
2-Deoxy-D-[1-14C] glucose was infused to later determine the glucose 
disposal rate in the tissues. After the glucose bolus, blood samples (15 µl) 
were collected at the timepoints 0, 5, 15, 25, 35, 55 min after bolus infusion. 
Once the glucose measurements were constant for at least 30 min at a fixed 
glucose infusion rate, the steady state phase was achieved. During the steady 
state period, blood samples (50 µl) were collected at every 10 min for the 
measurement of steady state parameters. At the end of the experiment, mice 
were sacrificed by a lethal dose of isofluran and brain, liver, WAT and skeletal 
muscle were dissected and stored at -80°C. 
 
 
2.2.7.3 Determination of the glucose turnover rate (mg/[kg*min]) 
 
To determine the glucose turnover rate, the D-[3-3H] glucose radioactivity in 
the plasma was assessed. Therefore, the plasma samples of basal and 
steady state period were deproteinized with 0.3 M Ba(OH)2 and 0.3 M ZnSO4 
followed by the evaporation of 3H2O, using a liquid scintillation counter 
(Beckmann, Krefeld, Germany).  
 
To calculate the glucose turnover rate, the infusion rate of tracer solution 
(dpm/min) was divided by the glucose specific activity (dpm/mg) in the 
plasma. The result was then corrected for body weight of the animals. 
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2.2.7.4 Calculation of the hepatic glucose production (HGP) 
 
Hepatic glucose production was calculated as the difference between the rate 
of glucose appearance and the infusion rate of glucose. 
 
 
2.2.7.5 Determination of the in vivo glucose uptake in the tissues 
 
For the determination of the in vivo glucose uptake in WAT, brain and skeletal 
muscle, the tissues were homogenized and 2-Deoxy-D-[1-14C] glucose (2DG) 
was separated from 2-Deoxy-D-[1-14C] glucose-6-phosphate (2DG6P) by 
using ion exchange chromatography columns (Poly-Prep® Prefilled 
Chromatography Columns, AG®1-X8 formate resin, 200 - 400 mesh dry; Bio 
Rad Laboratories). The 2-Deoxy-D-[1-14C] glucose radioactivity in the plasma 
was directly measured in the liquid scintillation counter (Beckmann, Krefeld, 
Germany). The calculation of the in vivo glucose uptake (nmol/[g*min]) of the 
tissues is based on the accumulation of 2DG6P in the respective tissue and 
the disappearance rate of 2DG from the plasma and was calculated as 
described previously (156). 
 
 
2.2.8 Ablation of Kupffer cells (KCs) 
 
To efficiently ablate the Kupffer cells in the liver, the mice received a single 
1 ml intraperetonal injection of clodronate liposomes (157) 2 days before the 
experiment. To confirm the ablation of the KCs, a MAC-2/Galectin-3 antibody 
(#CL8942AP; Cedarlane Laboratories Ltd, Burlington, ON, Canada) staining 
was performed. 
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2.2.9 Glucose-induced insulin secretion of isolated pancreatic islets 
 
To assess the glucose-induced insulin secretion of isolated pancreatic islets, 
the pancreatic islets were isolated as described previously (158) by a 
collagenase technique. Then, the islets were maintained overnight in RPMI 
1640 culture medium supplemented with 10% FCS, 2 mM glutamine, 
100 µg/ml streptomycin and 100 units of penicillin at 37°C in a humidified 
atmosphere (5% CO2 in the air). Afterwards, the islets were preincubated in 
HEPES buffer (pH 7.4) containing 125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 
1.28 mM CaCl2, 3 mM glucose and 1 mg/ml BSA for 30 min at 37°C. Batches 
of 6 to 9 islets were subsequently incubated with either 3 mM or 11 mM 
glucose for 30 min at 37°C. To stop the incubation, batches were chilled on 
ice and samples were taken for the analysis of insulin by the TPX plate reader 
(ArcDia International Oy Ltd, Turku, Finland) (159). The resting islets were 
collected for the quantification of dsDNA in the islets using the Pico-Green 
dsDNA quantification reagent kit (Invitrogen, Karlsruhe, Germany).  
 
 
2.2.10 Diethylnitrosamine (DEN) treatment 
 
The chemical diethylnitrosamine (DEN) causes DNA alkylation, leading to 
mismatches during replication. This results in DNA mutations and ultimately to 
the development of hepatocellular carcinoma (HCC) (160). 
 
 
2.2.10.1 Long-term treatment: 
 
Mice at 15 days of age were injected with 25 mg/kg DEN into the peritoneal 
cavity and sacrificed after 32 weeks. Blood samples were collected at week 
12 and week 24 for further analysis. After dissection of the WAT, skeletal 
muscle and liver, HCC were counted and tissues were stored at -80°C. 
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2.2.10.2 Short-term treatment: 
 
Animals at the age of 12 weeks received an i.p. injection of 100 mg/kg DEN 
and sacrificed after indicated timepoints. Afterwards, blood samples were 
collected and liver, skeletal muscle and WAT were dissected and stored at 
-80°C. 
 
 
2.2.11 Analysis of serum protein and cytokine concentrations  
 
Serum levels of AST, ALT, cholesterol and TG were determined in the 
diagnostic laboratory of the University Hospital Cologne using a standard 
protocol. The determination of IL-6, IL-10 and TNF-α levels in the sera was 
conducted using a cytometric bead array (CBA) (#552364, BD Biosciences) 
with a FACS Calibur (BD Biosciences) according to the manufacture’s 
protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
____________________________________________________________________________________________________________________________ 
 29 
2.3 Molecular biology 
 
2.3.1 Isolation of genomic DNA 
 
To isolate genomic DNA, mouse tail biopsies or tissues were taken and 
digested in 600 µl tail lysis buffer (100 mM Tris pH 8.5, 5 mM EDTA, 0.2% 
(w/v) SDS, 0.2 M NaCl, 500 mg/ml Proteinase K) in a thermomixer 
(Eppendorf, Hamburg, Germany) at 56°C over night. The DNA was 
subsequently precipitated by adding an equivalent volume of 2-propanol 
(100%). After centrifugation and a wash step with 70% EtOH, the DNA pellet 
was dried and re-dissolved in 50-100 µl TE-buffer (10 mM Tris/HCl [pH=8], 
1 mM EDTA) containing 50 µg/ml RNAseI.  
 
 
2.3.2 Quantification of nucleic acids 
 
The concentration of DNA and RNA was determined by measuring the 
sample absorption at 260 nm with a NanoDrop ND-1000 UV-Vis 
spectrophotomoter (Peqlab, Erlangen, Germany). An optical density at 
260 nm (OD260) of 1 corresponds to approximately 50 µg/ml of double 
stranded DNA and to 38 µg/ml of RNA. The absorption at 280 nm (OD280) was 
used for protein content in the samples. As an index of DNA/RNA purity the 
ratio of OD260/OD280 was used. A ratio of 2 refers to pure DNA or RNA and 
lower values display protein contaminations of the probes.  
 
 
2.3.3 Southern blot analysis 
 
10-15 µg of genomic DNA were digested overnight at 37°C, using BglI. 
Seperation of DNA was performed electrophoretically on an 0.8% (w/v) 
agarose gel at 30 V with subsequent transfer on a HybondTM-N+ nylon 
membrane (Amersham, Braunschweig, Germany) by an alkaline capillary 
transfer (161). The followed crosslink of the DNA to the membrane was 
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performed by baking the membrane at 80°C for 20 min. Meanwhile the 
α[32P]-dCTP labeled probe was amplified by PCR using the LaddermanTM DNA 
Labeling Kit (TaKaRa; Cambrex Bio Science, Verviers, Belgium) with 
customized primers (Table 3). The Membranes were then equilibrated in 2 x 
SSC and prehybridized at 65°C for 4 h in hybridization solution (1 M NaCl, 1% 
(w/v) SDS, 10% (w/v) dextran sulfate, 50 mM Tris-HCl (pH 7.5), 250 µg/ml 
sonicated salmon sperm DNA). Afterwards, the radioactively labeled probe 
was added to the prehybridization solution for hybridization of the probe to its 
corresponding sequence on the nylon membrane (overnight at 68°C in a 
rotating cylinder). Unspecifically bound probe was removed by washing the 
membrane at 68°C for 10 – 20 min, until 20 – 80 cps were reached 
(monitored by a Geiger Müller Counter). The initial wash was performed with 
2 x SSC / 0.1% (w/v) SDS, followed by 1 x SSC / 0.1% (w/v) SDS, if needed. 
The membrane was then sealed in a plastic bag and exposed to an X-ray film 
(Kodak XAR-5 or BioMAX MS; Eastman Kodak) at -80°C in an appropriate 
cassette. Films were developed in an automatic developer (Agfa, Köln, 
Germany). 
 
Table 3: List of oligonucleotides used for Southern probe generation  
Probe name Primer name Sequence (5’-3’) 
IL-6R_S_Probe_fwd TTG TAG TCT CCA CCC ACA AGC C  
probe B 
 IL-6R_S_Probe_rev AGC GAG CAA CCT CAG ACT CAG A 
 
 
2.3.4 Polymerase chain reaction (PCR) 
 
To genotype mice for the presence of loxP flanked exons or Cre transgenes, 
the PCR (162, 163) method was used, either performed in a Thermocycler 
iCycler PCR machine (BioRad, München, Germany) or in a Peltier Therman 
Cycler PTC-200 (MJ Research, Waltham, USA). The total reaction volume of 
each PCR was 25 µl, containing a minimum of 50 ng DNA template, 25 pmol 
of each customized oligo (Table 4), 25 µM dNTP mix, 1 x polymerase buffer 
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and 1 U of polymerase. A standard PCR program started with 5 min of 
denaturation at 95°C, followed by 35 - 40 cycles, consisting of denaturation at 
95°C for 45 sec, annealing at the oligonucleotide-specific temperature for 
30 sec and elongation for 30 sec at 72°C. A final elongation step at 72°C for 
7 min was added at the end. 
 
Table 4: List of oligonucleotides used for PCR 
Name Sequence TAnnealing [°C] Orientation 
5GK12 CCG CGG GCG ATC GCC TAG G 55°C sense 
5IL6Ex3 CCA GAG GAG CCC AAG CTC TC  55°C antisense 
3IL6A TAG GGC CCA GTT CCT TTA T 55°C antisense 
MyD88 1  GGG AAT AAT GGC AGT CCT CTC CCA G 55°C sense 
MyD88 2  GGA TCA TCT CCT GCA CAA ACT CG 55°C antisense 
MyD88 Del  CAG TCT CAT CTT CCC CTC TGC C 55°C antisense 
 
 
2.3.5 RNA extraction 
 
To isolate total RNA, snap-frozen tissues were thawed and homogenized in 
1 ml TriFast reagent using a polytron homogenizer. After a 5 min incubation 
step at RT, the homogenate was centrifuged for 10 min at 4°C and the 
supernatant was transferred into a new vial. A following phenol-chloroform 
extraction and precipitation with isopropanol were performed according to the 
manufacturers instruction of the TriFast reagent. The treatment with 
RNase-free DNase was necessary, when exon-spanning probes were not 
available. The RNA concentration was analyzed using a NanoDrop ND-1000 
UV-Vis spectrophotometer (Peqlab, Erlangen, Germany) and diluted to an 
final concentration of 400 ng/µl. 
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2.3.6 Quantitative real-time PCR 
 
For the quantitative real-time PCR analysis, 4 µg of each RNA sample was 
reversely transcribed using the Eurogentec RT Kit (Eurogentec, Cologne, 
Germany) according to manufacturer’s instructions. The resulted cDNA was 
subsequently amplified using TaqMan® Universal PCR-Master Mix, NO 
AmpErase UNG with the specific TaqManR Assay on demand kits (Applied 
Biosystems, Foster City, USA) (Table 5). The quantitative RT-PCR was 
performed on an ABI-PRISM 7700 Sequence Detector (Applied Biosystems, 
Foster City, USA) and were linear over 4 orders of magnitude. 
 
Table 5: List of Taqman gene expression assays 
Gene name Order name Order number 
Bcl-2–associated X protein (Bax) Bax Mm00432050_m1 
B-cell lymphoma 2 (Bcl-2) Bcl2 Mm00477631_m1 
Bcl-2-like protein 11 (Bim) Bcl2l11 Mm00437795_m1 
Cluster of differentiation 68 (CD-68) CD68 Mm03047340_m1 
DNA damage-inducible transcript 3 (CHOP) Ddit3 Mm00492097_m1 
Egf-like module containing, mucin-like, hormone 
receptor-like 1 (F4/80) Emr1 Mm00802530_m1 
Glucose-6-phosphatase (G6Pase) G6pc Mm00839363_m1 
Glucokinase (GK) Gck Mm00439129_m1 
Interleukin 10 (IL-10) Il10 Mm00439616_m1 
Interleukin 6 (IL-6) Il6 Mm00446190_m1 
Interleukin 6 receptor, alpha (IL-6Rα) il6ra Mm00439649_m1 
Integrin alpha M (Itgam) Itgam Mm00434455_m1 
Integrin alpha X (Itgax) Itgax Mm00498698_m1 
Leukemia inhibitory factor (LIF) Lif Mm00434761_m1 
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Lectin, galactose binding, soluble 3 (MAC-2) Lgals3 Mm00802901_m1 
Chemokine (C-C motif) ligand 2 (MCP-1) CCL2 Mm00441242_m1 
Chemokine (C-C motif) ligand 7 (MCP-3) CCL7 Mm00443113_m1 
Chemokine (C-C motif) ligand 3 (MIP-1α) CCL3 Mm00441258_m1 
Chemokine (C-C motif) ligand 4 (MIP-1β) CCL4 Mm00443111_m1 
Myeloid differentiation primary response gene 88 
(MyD88) Myd88 Mm01351743_g1 
Chemokine (C-C motif) ligand 5 (RANTES) CCL5 Mm01302428_m1 
Tumor necrosis factor alpha (TNF-α) TNFalpha Mm00443258_m1 
Tumor necrosis factor receptor 1 (TNFR1) Tnfrsf1b Mm00441889_m1 
 
 
The relative expression of genes was adjusted for total RNA content by 
glucuronidase β (GUSB) and hypoxyanthine guanine phosphoribosyl 
transferase 1 (HPRT-1) mRNA quantitiatve real-time PCR. Calculations were 
performed by a comparative method (2-(ΔΔCT)). In brief, the amplification plot is 
the plot of fluorescence versus PCR number. The threshold cycle value (ct) is 
the fractional PCR cycle number at which the fluorescent signal reached the 
detection threshold. Therefore, the input cDNA copy number and ct are 
inversely related. Data were analyzed with the Sequence Detector System 
(SDS) software version 2.1 (ABI) and ct value was automatically converted to 
fold change RQ value ((RQ) = 2−(ΔΔCT)). The RQ values from each gene were 
then used to compare the gene expression across all groups. 
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2.4 Biochemistry 
 
2.4.1 Protein extraction 
 
For generation of tissue protein lysates, snap-frozen tissues were 
homogenized in 1 ml tissue lysis buffer (50 mM HEPES (pH 7.4), 1% (v/v) 
Triton X-100, 0.1 M NaF, 10 mM EDTA, 50 mM NaCl, 10 mM sodium 
orthovanadate, 0,1% (w/v) SDS, 10 µg/ml aprotinin, 2 mM benzamidine, 
2 mM phenylmethylsulfonyl fluoride (PMSF)), using a polytron homogenizer 
(IKA Werke, Staufen, Germany). The tissue extracts were then centrifuged 
1 h at 4°C to separate supernatant from cell debris and the protein 
concentration of the cleared supernatant was determined using a Bradford 
assay. A final concentration of 10 µg/µl in 1 x SDS loading buffer (62,5 mM 
Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% (w/v) glycerol, 50 mM DTT, and 0.01% 
(v/v) bromophenol blue) was then used for the following Western blot 
analysis. Before loading of samples onto a Western blot gel, protein solutions 
were boiled at 95°C for 5 min in order to denaturate proteins. 
 
To generate nuclear protein extracts from liver, the liver tissue was carefully 
homogenised in hypotonic solution (10 mM HEPES [pH 7.6], 10 mM KCl, 
2 mM MgCl2, 0.1 mM EDTA, supplemented with complete mini protease 
inhibitor cocktail tablets) and incubated on ice for 10 min. NP-40 was added to 
1% (v/v), incubated for 5 min at 4°C and subsequent centrifugation 
(13000 rpm) for 1 min at 4°C. After removing the cytoplasmic fraction, the 
nuclear pellet was washed in hypotonic buffer and resuspended in high salt 
buffer (20 mM HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 
0.2 mM EDTA, 10% (v/v) glycerol, completed with protease inhibitor cocktail). 
After additional incubation for 30 min on ice and centrifugation at 4°C for at 
least 1 h, the nuclear protein fraction was transferred into a new vial, diluted to 
4 µg/µl and stored at -80°C. If needed, the nuclear extracts were thawed on 
ice and used for the experiment. 
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2.4.2 Western blot analysis 
 
The protein samples were separated on 10 – 15% (v/v) SDS polyacrylamide 
gels and blotted onto PVDF membranes (Bio-Rad, München, Germany). The 
membranes were then blocked with 10% (v/v) blocking reagent for 2 h at RT. 
Subsequently, primary antibodies (Table 6) diluted in 5% (v/v) blocking 
reagent were applied overnight at 4°C. After 5 x washing with 1 x TBS / 0.1% 
(v/v) Tween 20 for 5 min each, the respective secondary antibody was applied 
for 1 h at RT, followed by additional 5 x washing. The membranes were then 
incubated for 1 min in Pierce ECL Western Blocking Substrate and exposed 
to chemiluminescence films (Amersham, Braunschweig, Germany). Films 
were developed in an automatic developer (Kodak, Germany).  
 
Table 6: List of primary antibodies used for Western blot analysis 
Name Order number Distributor Dilution 
AKT #4685 Cell signaling (Danvers, MA, USA) 1:1000 
Beta actin ab8227 Abcam (Cambridge, UK) 1:5000 
Calnexin 208880 Calbiochem (Darmstadt, Germany) 1:5000 
ERK1/2 #9102 Cell signaling (Danvers, MA, USA) 1:1000 
G6Pase sc-25840 Santa Cruz (Heidelberg, Germany) 1:500 
IκBα #4812 Cell signaling (Danvers, MA, USA) 1:1000 
MyD88 Ab2064 Abcam (Cambridge, UK) 1:1000 
p38 #9212 Cell signaling (Danvers, MA, USA) 1:1000 
p65 sc-372 Santa Cruz (Heidelberg, Germany) 1:1000 
Phospho-AKT 
(Ser473) #4060 Cell signaling (Danvers, MA, USA) 
1:1000 
Phospho-p65 
(Ser536) #3033 Cell signaling (Danvers, MA, USA) 
1:1000 
Phospho-ERK1/2 
(Thr202/Tyr204) #4377 Cell signaling (Danvers, MA, USA) 
1:1000 
Phospho-IκBα  
(Ser32) #2859 Cell signaling (Danvers, MA, USA) 
1:1000 
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Phospho-p38 
(Thr180/Tyr182) #9215 Cell signaling (Danvers, MA, USA) 
1:1000 
Phospho-SAPK/JNK 
(Thr183/Tyr185) #4668 Cell signaling (Danvers, MA, USA) 
1:1000 
Phospho-STAT-3 
(Tyr705) #9145 Cell signaling (Danvers, MA, USA) 
1:1000 
SAPK/JNK #9258 Cell signaling (Danvers, MA, USA) 1:1000 
 
 
2.4.3 Electrophoretic mobility shift assay (EMSA) 
 
For the EMSA, 100 ng of EMSA probe DNA (Table 7) was radioactively 
end-labelled in a 25 µl reaction mix containing 2.5 µCi γ[32P]-dATP and 25 U 
T4 polynucleotide kinase. After 10 min incubation at 37°C the probe was 
purified from nonincorporated nucleotides with MicroSpinTM G-20 columns 
(GE Healthcare, Munich, Germany) according to manufacturer’s guidelines. 
The binding reaction was performed by incubating 4 µg of nuclear protein 
extracts with 0.5 ng of  32P-labelled probe and 2 µg poly(dI-dC) for 30 min at 
RT and stopped by adding 2 µl of tracking dye (0.25% bromphenol blue, 
0.25% xylene cyanol and 30% Glycerol). The following electrophoresis was 
performed as previously described (164).  
 
Table 7: EMSA probes 
Name Order number Sequence Distributor 
SP-1 #sc-2502 
ATT CGA TCG GGG CGG GGC 
GAG C 
Santa Cruz 
(Heidelberg, Germany) 
STAT-3 #sc-2571 
GAT CCT TCT GGG AAT TCC 
TAG ATC 
Santa Cruz 
(Heidelberg, Germany) 
 
2.4.4 Enzyme-linked immunosorbent assay (ELISA) 
 
To determine the concentrations of sIL-6Rα, leptin and insulin in the serum, 
the specific ELISA Kits (Table 8) were used according to the manufacturer’s 
guidelines. The measurements were done on a Precision Microplate Reader 
(Emax; Molecular Devices GmbH). 
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Table 8: List of ELISA kits 
Name Order number Distributor 
Mouse IL-6 sR ELISA #DY1830 R&D systems (Wiesbaden, Germany) 
Mouse leptin ELISA #90030 Crystal Chem. (Downers Grove, IL, USA) 
Rat/Mouse insulin ELISA #INSKR020 Crystal Chem. (Downers Grove, IL, USA) 
 
 
2.4.5 Histological analysis and immunohistochemistry 
 
2.4.5.1 Immunohistochemistry 
 
For immunohistochemistry, the tissues were embedded in tissue freezing 
medium directly after dissection. If needed, the tissues were sectioned on a 
cryostat and stained as indicated. The cryostat sections of liver and 
pancreatic tissue were stained with hematoxylin and eosin (H&E) for general 
histology and to visualize morphological changes. The Kupffer cells were 
stained on cryostat sections of liver tissue using MAC-2/Galectin-3 antibody 
(#CL8942AP; Cedarlane Laboratories Ltd, Burlington, ON, Canada). For the 
acquisition of digital images, the stained sections were viewed under a Zeiss 
Axioskop equipped with a Zeiss AxioCam using the Spot Advanced 3.0.3 
software (Carl Zeiss MicroImaging GmbH, Oberkochen).  
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2.5 Computer analysis  
 
2.5.1 Densitometrical analysis 
 
Protein content of Western blots was analyzed desitometrically by measuring 
the pixeldensity per mm2 using either ImageJ (National Institutes of Health, 
Bethesda, USA) or Quantity one software (Biorad). After substracting the 
background and normalizing to an internal loading control, the relative density 
of control animals were set to 100% and compared to the relative density of 
indicated animals. 
 
 
2.5.2 Quantitation of pancreatic islet mass 
 
Quantitation of average pancreatic islet mass was determined on serial 
sections of pancreata stained with H&E. For the acquisition of digital images, 
the stained sections were viewed under a Zeiss Axioskop equipped with a 
Zeiss AxioCam using the Spot Advanced 3.0.3 software (Carl Zeiss 
MicroImaging GmbH, Oberkochen). The Quantification of pancreatic islet size 
was performed using AxioVision 4.2 (Carl Zeiss MicroImaging GmbH, 
Oberkochen, Germany). 
 
 
2.5.3 Statistical methods 
 
All data sets were analyzed by using a two-tailed unpaired student’s t test for 
statistical significance. All p values below 0.05 were considered as statistical 
significant. All displayed values are means ± SEM. * p = 0.05; ** p = 0.01; 
*** p = 0.001 versus controls. 
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3. Results 
 
3.1 The effect of hepatic IL-6Rα signal transduction on glucose 
homeostasis  
 
Obesity is a state of chronic, low-grade inflammation, characterized by 
elevated plasma concentrations of inflammation-associated factors, such as 
interleukin-6 (IL-6) and interleukin-1β (IL-1β), which in turn may contribute to 
the development of insulin resistance (65-68). The function of IL-6 signaling in 
the context of promoting insulin resistance under obesity is controversially 
discussed (77). 
 
3.1.1 Generation of hepatocyte specific IL-6Rα knock out mice 
 
To address the role of inflammatory signaling downstream of the IL-6Rα in 
hepatocytes on insulin action and glucose homeostasis in vivo, we generated 
mice lacking the IL-6Rα selectively in hepatocytes (IL-6RαL-KO). Therefore we 
crossed mice expressing the Cre recombinase under the control of the 
ALFP-promotor (165) with mice harbouring the loxP-flanked IL-6Rα gene 
(Fig. 9 A) and further intercrossing of siblings yielded IL-6RαL-KO mice. The 
littermates lacking expression of Cre recombinase (IL-6RαFL/FL) served as 
controls throughout the experiments. 
 
To determine the specificity and efficiency of the deletion of loxP-flanked 
exons 2 and 3 of the IL-6Rα gene, we performed Southern blot analysis on 
genomic DNA isolated from liver, WAT, skeletal muscle and tails of IL-6RαL-KO 
and control mice. While the 9kb loxP-flanked band was detectable in all 
analyzed tissues of both groups, only the liver of IL-6RαL-KO showed the 6.3kb 
deleted allele of the IL-6Rα gene. This analysis revealed that the expression 
of the Cre recombinase under the control of the ALFP-promotor efficiently 
excised the loxP-flanked exons 2 and 3 of the IL-6Rα gene exclusively in the 
liver of IL-6RαL-KO mice (Fig. 9 B). 
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Fig. 9: Targeting strategy and confirmation of the IL-6RαFL/FL allele 
(A) Targeting strategy for the generation of the conditional IL-6Rα allele. Upper lane shows 
the wildtype (WT) IL-6Rα gene comprising exons 2, 3, 4, 5, and 6. The loxP-flanked exons 2 
and 3 of the IL-6Rα allele (FL) are shown in the middle lane and the Cre loxP mediated 
excision of these exons is shown at the bottom (Δ). (B) Southern blot analysis of the FL and Δ 
allele on BglI-digested DNA from liver (L), WAT (W), skeletal muscle (M) and tail (T) of control 
and IL-6RαL-KO mice using probe B.  
 
Additionally, we performed quantitative RT-PCR for IL-6Rα mRNA expression 
using mRNA isolated from liver tissues. As shown in Figure 10 A, the 
expression of IL-6Rα mRNA was completely blunted in IL-6RαL-KO mice 
compared to control animals, implying an efficient reduction of IL-6Rα mRNA 
in hepatocytes. 
 
Besides the classical IL-6 signaling that is restricted to those cell types 
expressing the membrane bound form of the IL-6Rα, another mechanism 
termed IL-6 trans-signaling exists that uses a soluble form of the IL-6Rα to 
ensure IL-6 signaling in cells, which do not express the membrane bound 
form of the IL-6Rα (166). To ascertain whether the loss of IL-6Rα expression 
in the liver results in decreased levels of circulating sIL-6Rα, serum levels for 
sIL-6Rα from IL-6RαL-KO and control mice were determined by ELISA 
(Fig. 10 B). As the levels of circulating sIL-6Rα were similar, the results 
indicated that the specific inactivation of the IL-6Rα in hepatocytes does not 
affect the amount of circulating sIL-6Rα concentrations.  
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Moreover, the lack of hepatic IL-6Rα expression was unable to affect liver 
weight as well as histomorphological liver structure, shown by H&E staining of 
liver sections (Fig. 10 D and E).  
 
Fig. 10: Liver specific ablation of the IL-6Rα  gene 
(A) Relative mRNA expression in livers of IL-6RαL-KO and control mice measured by 
quantitative RT-PCR (n=6/genotype). (B) Amount of circulating sIL-6Rα concentrations in the 
blood serum of 8 weeks old mice, measured by ELISA (n=10/genotype). (C) Liver weight of 
IL-6RαL-KO and control mice at week 20 (n=8-10/genotype). (D) Histomorphological liver 
structure, analyzed by H&E staining of liver sections from IL-6RαL-KO and control mice. Data 
are displayed as means ± SEM. *** p ≤ 0.001 versus controls 
 
Taken together, these experiments demonstrate that the IL-6RαL-KO mouse 
lacks the IL-6Rα specific in hepatocytes without affecting liver morphology 
and can be used as a reliable tool to analyze the hepatocyte specific role of 
the IL-6 signaling in glucose homeostasis.  
 
 
3.1.2 IL-6RαL-KO mice exhibit unaltered energy homeostasis  
 
The role of IL-6 signaling in energy homeostasis, obesity and insulin 
resistance is not clear yet and remains controversially debated. Some studies 
could show, that conventional ablation of IL-6 signaling in mice leads to 
mature onset obesity (167). Nevertheless, the responsible tissue, which 
contributes to the development of obesity, remained unidentified.  
Results 
____________________________________________________________________________________________________________________________ 
 
 42 
To investigate the role of hepatic IL-6 signaling on energy homeostasis, we 
analyzed body weight, epigonadal fat pad mass and body fat content in 
IL-6RαL-KO and control mice (Fig. 11). The weight gain in response to normal 
chow diet (NCD) feeding from week 3 to week 19 of age (Fig. 11 A), as well 
as at week 20 of age (Fig. 11 B), was unaltered between IL-6RαL-KO and 
control mice. Consistently with the unaltered weight gain, epigonadal fat pad 
mass and body fat was indistinguishable between IL-6RαL-KO and control mice 
(Fig. 11 C). 
 
Fig. 11: IL-6RαL-KO mice show unaltered adiposity 
(A) Average bodyweight was monitored from week 3 to week 19 of IL-6RαL-KO and control 
mice (n=12-16/genotype). (B) Average bodyweight at week 20 from both groups 
(n=12-16/genotype). (C) Epigonadal fat pad mass and total body fat content of IL-6RαL-KO and 
control mice at week 20. Body fat content was determined by using nuclear magnetic 
resonance (n=12-16/genotype). Displayed values are means ± SEM. 
 
Moreover, the circulating leptin levels were comparable between both groups 
indicating similar adiposity in the two groups of mice (Fig. 12 A). Similar 
adiposity was accompanied with equal food consumption of IL-6RαL-KO and 
control mice (Fig. 12 B). Additionally, energy expenditure was determined by 
indirect calorimetry using the PhenoMaster system. However, the analysis 
revealed no obvious alterations in O2 consumption and CO2 production 
between the groups (Fig. 12 C and D).  
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Fig. 12: Unchanged energy homeostasis in mice lacking hepatic IL-6Rα  signaling 
(A) Amount of circulating leptin concentrations in the blood serum of 8 and 16 weeks old 
mice, measured by ELISA (n=10/genotype). (B) Average daily food intake over 48 h of 10 
weeks old IL-6RαL-KO and control mice (n=7-9/genotype). (C-F) Daily and nightly (C) O2 
consumption, (D) CO2 production, (E) respiratory exchange ratio and (F) locomotor activity of 
IL-6RαL-KO and control mice at 10 weeks of age. VO2, VCO2 and locomotor activity were 
determined in chambers of the PhenoMaster System by indirect calorimetry 
(n=7-9/genotype). Displayed values are means ± SEM. 
 
In addition, the respiratory exchange ratio (RER), an indicator for the 
preferred metabolic source of energy, lipids or carbohydrates, remained 
unaltered between IL-6RαL-KO and control mice, indicating that both 
genotypes utilized the same substrates for oxidative metabolism (Fig. 12 E). 
To determine whether the deletion of IL-6Rα in hepatocytes impacts on 
locomotor activity, basal locomotor activity of IL-6RαL-KO and control mice was 
determined. At week 10 of age, no obvious difference in locomotor activity 
was observed in IL-6RαL-KO mice compared to control mice (Fig. 12 F).  
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In summary, the lack of hepatic IL-6Rα signaling, does not affect weight gain, 
adiposity and energy homeostasis. 
 
3.1.3 IL-6RαL-KO mice exhibit impaired glucose homeostasis and insulin 
sensitivity 
 
Given the observation that systemic IL-6 concentrations are elevated in 
obesity and in patients suffering from type-2-diabetes (168), it was generally 
assumed that IL-6 somehow contributes to the development of insulin 
resistance and impaired glucose homeostasis (169). Additionally it has been 
shown that IL-6 inhibits insulin signaling ex vivo in mouse derived hepatocytes 
by inhibiting IRS-1 phosphorylation, mediated by induction of the IL-6 target 
gene SOCS-3 (81). To study the role of hepatic IL-6 signaling in glucose 
homeostasis, we first assessed the glucose metabolism in IL-6RαL-KO and 
control mice. Therefore we measured blood glucose concentrations under 
fasted and random fed conditions. Normal chow diet feeding of control and 
IL-6RαL-KO mice exhibited normal blood glucose levels under fasting and 
random feeding conditions (Fig. 13 A). Furthermore, we investigated the 
glucose homeostasis by performing a glucose tolerance test (GTT) with both 
groups (Fig. 13 B). Although basal blood glucose concentrations were 
unaltered, the IL-6RαL-KO mice exhibited a significantly impaired tolerance to 
glucose during the GTT compared to control mice. 
 
Fig. 13: IL-6RαL-KO mice exhibit decreased glucose tolerance 
(A) Monitored blood glucose levels under fasted and random fed conditions of IL-6RαL-KO and 
control mice at 8 weeks of age (n=10-14/genotype). (B) Glucose tolerance test (GTT) 
monitored over 120 min of 11 weeks old IL-6RαL-KO and control mice (n=10-13/genotype). 
Displayed values are means ± SEM. * p ≤ 0.05; *** p ≤ 0.001 versus controls 
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To differentiate whether this impaired glucose tolerance develops as a 
consequence of decreased glucose induced insulin secretion from β-cells 
upon glucose stimulation, we first determined the insulin release under 
glucose challenge as measured by the circulating levels of insulin during the 
GTT (Fig. 14 A).  
 
Fig. 14: Impaired insulin sensitivity in IL-6RαL-KO mice 
(A) Measured insulin concentration in sera of IL-6RαL-KO and control mice during the glucose 
tolerance test by ELISA (n=9-13/genotype). (B) Histomorphological structure of pancreata, 
analyzed by H&E staining of pancreas sections from IL-6RαL-KO and control mice. 
(C) Average pancreatic islets mass, determined by analyzing H&E stained pancreas sections 
(n=8/genotype). (D) Scatter plot of glucose-stimulated insulin secretion (ng/ng DNA) of 
isolated islets from IL-6RαL-KO and control mice. Incubation of 6-9 islets at low (3 mM) or high 
glucose (11 mM) for 30 min was performed with different groups of batches. For 
measurements of low glucose, 6-8 batches (n=3-5/genotype) and for high glucose, 10-13 
batches (n=5/genotype) were used. The fold change of insulin secretion after stimulation with 
high glucose is shown on the right. (E) Insulin tolerance test displayed over 60 min of 12 
weeks old IL-6RαL-KO and control mice (n=10-13/genotype). Displayed values are means ± 
SEM. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 versus controls 
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Additionally, pancreatic islet mass, β-cell function and the ability of insulin to 
lower blood glucose via insulin tolerance test (ITT) were investigated. 
Although the glucose stimulated insulin secretion during the GTT (Fig. 14 A) 
and the pancreatic islet mass (Fig. 14 B and C) were not significantly altered 
between control and IL-6RαL-KO mice, the IL-6RαL-KO mice exhibited 
compromised β-cell function and impaired insulin tolerance in ITTs. The β-cell 
function was determined in vitro in primary pancreatic islets, isolated from 
IL-6RαL-KO and control mice, by analyzing their ability of secreting insulin in 
response to glucose stimulation (Fig. 14 D). While isolated pancreatic islets of 
IL-6RαL-KO mice exhibit higher insulin secretion in response to low-glucose 
concentrations compared to islets of control mice, the ability to promote 
insulin secretion at high glucose concentrations was significantly decreased in 
islets of IL-6RαL-KO mice. Furthermore, consistent with the decreased 
tolerance to glucose during the GTT, the ability of insulin to lower blood 
glucose during the ITT was also significantly reduced (Fig. 14 E). 
 
In summary, these experiments clearly demonstrated, that the lack of hepatic 
IL-6 signaling not only impairs the ability of β-cells to promote insulin secretion 
at high glucose concentrations, but also translates into the development of 
systemic insulin resistance and glucose intolerance. 
 
 
3.1.4 IL-6RαL-KO mice exhibit counteracting actions on hepatic glucose 
metabolism  
 
To determine the contribution of different insulin responsive tissues (e.g. liver, 
skeletal muscle and WAT), in altering insulin sensitivity and glucose 
homeostasis and thereby leading to the development of systemic insulin 
resistance, we performed euglycemic-hyperinsulinemic clamp studies in 
IL-6RαL-KO and control mice. In response to a constant infusion of insulin, 
resulting in hyperinsulinemia in vivo during the course of this study, a variable 
dose of glucose was infused to maintain euglycemia. Consistent with the 
impaired insulin sensitivity observed during the ITT, a decreased 
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responsiveness to insulin was also observed during this study. To achieve the 
comparable euglycemic state during the steady state phase of the experiment 
in both groups (Fig. 15 A), IL-6RαL-KO mice exhibited significantly reduced 
glucose infusion rate compared to control mice (Fig. 15 B). Consistent with 
these findings, the whole body glucose disposal rate was significantly reduced 
in IL-6RαL-KO compared to control mice during the steady state phase 
(Fig. 15 C). Since insulin maintains glucose homeostasis under conditions of 
high caloric intake by inhibiting hepatic glucose production (HGP), we 
investigated the HGP in IL-6RαL-KO and control mice during the eulycemic-
hyperinsulinemic clamps. Although under the basal state the HGP remained 
elevated but unaltered between the two groups of animals, the ability of 
insulin to inhibit HGP was comparable between both groups during the steady 
state phase of the clamp study (Fig. 15 D). 
 
Fig. 15: Altered regulation of glucose homeostasis in IL-6RαL-KO mice 
(A) Monitored blood glucose levels over 230 min during euglyemic-hyperinsulinemic clamp 
studies of IL-6RαL-KO and control mice (n=12/genotype). (B) Respective glucose infusion rate 
to maintain euglycemia during the euglyemic-hyperinsulinemic clamp study of IL-6RαL-KO and 
control mice (n=12/genotype). (C) Calculated glucose disposal rate during the basal and 
steady state phase of the clamp study (n=12/genotype). (D) Calculated HGP during the basal 
and steady state phase of the clamp study (n=12/genotype). Displayed values are means ± 
SEM. * p ≤ 0.05; *** p ≤ 0.001 versus controls 
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To maintain stable and constant glucose homeostasis via HGP, two key 
metabolic pathways, gluconeogenesis and glycogenesis, play an essential 
role. Gluconeogenetic key enzymes, e.g. G6Pase, had been reported to 
depend on hepatic IL-6 signaling (85). Therefore we determined hepatic 
G6Pase mRNA expression by quantitative RT-PCR and G6Pase protein level 
in the liver from control and IL-6RαL-KO mice by Western blot analysis during 
basal and steady state phase of the euglycemic-hyperinsulinemic clamp 
studies. 
 
In consistency with the significant suppression of HGP during the steady state 
phase compared to the basal phase in both groups of animals, relative mRNA 
expression of G6Pase was also significantly reduced. Interestingly, the 
relative G6Pase mRNA expression during the steady state phase was 
significantly higher in IL-6RαL-KO mice compared to control mice (Fig. 16 A). In 
line with this observation, the protein level of G6Pase was also increased in 
the liver of IL-6RαL-KO mice compared to control mice during the steady state 
phase (Fig. 16 B). To sum up, these findings reveal a functional role of 
hepatic IL-6 signaling in the insulin-mediated suppression of G6Pase and 
thereby indicate the presence of a partial insulin resistance in the liver of 
IL-6RαL-KO mice. 
 
A key enzyme in the process of glycogenesis and glycolysis is the 
phosphorylation of glucose by the glucokinase (GK). Thereby glucose is 
converted to glucose-6-phosphate, which then enters the glycogenesis or the 
glycolysis pathway. To investigate whether hepatic IL-6 signaling plays a role 
in regulating glycogen synthesis through glucokinase in the liver, we decided 
to determine the mRNA expression of GK in the liver of control and IL-6RαL-KO 
mice by quantitative RT-PCR. Although insulin increased the mRNA 
expression of GK during the steady state phase compared to basal state in 
control mice, this elevation was significantly enhanced in IL-6RαL-KO mice 
compared to control mice (Fig. 16 C). To further address the effect of 
increased GK mRNA expression and decreased G6Pase suppression in 
IL-6RαL-KO mice on glycogen storage in the liver, we analyzed the hepatic 
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glycogen content of both groups. Thus, glycogen was extracted and 
measured from livers of mice after a 16h fasting period as well as at the end 
of the steady state phase during the euglycemic-hyperinsulinemic clamp 
study.  
 
Fig. 16: Counteracting actions on hepatic glucose metabolism in IL-6RαL-KO mice 
(A) Relative mRNA expression in livers of IL-6RαL-KO and control mice during basal and 
steady state phase of the clamp study (n=6/genotype). (B) Western blot analysis of liver 
lysates from indicated mice at both conditions by using G6Pase and AKT antibody. 
(C) Relative expression of GK mRNA in livers of both groups during basal and steady state 
phase (n=6/genotype). (D) Hepatic glycogen content, measured by using colorimetric glucose 
determination after enzymatic breakdown of glycogen into glucose (n=12/genotype). 
(E) Hepatic glycogen synthesis rate of IL-6RαL-KO and control mice was examined by 
3H-glucose incorporation into glycogen at the and steady state phase of the clamp study 
(n=12/genotype). Displayed values are means ± SEM. * p ≤ 0.05; *** p ≤ 0.001 versus 
controls. 
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While the glycogen content seemed unaffected between both conditions in 
control mice, the amount of glycogen during the steady state phase in mice 
lacking the hepatic IL-6Rα was significantly reduced (Fig. 16 D). To 
investigate whether this was an effect of reduced hepatic glycogen synthesis, 
we additionally determined the hepatic glycogen synthesis rate of IL-6RαL-KO 
and control mice during the steady state phase. To this end, we measured the 
3H-glucose incorporation into glycogen. Importantly, this analysis indicated a 
significant elevated glycogen synthesis rate in IL-6RαL-KO mice compared to 
control mice (Fig. 16 E). Thus, these data indicate impairment in the 
insulin-induced suppression of glycogenolysis in IL-6RαL-KO mice. 
 
Collectively, these findings support the assumption, that hepatic IL-6 signaling 
has counteracting actions on glucose metabolism in the liver; on one hand by 
suppressing G6Pase, which is required for gluconeogenesis and on the other 
hand by increasing GK, which is required for glycogen synthesis. 
Nevertheless, the disruption of hepatic IL-6 signaling has no dramatic effect 
on glucose homeostasis in the liver and seemed largely balanced. 
 
 
3.1.5 Mice lacking hepatic IL-6 signaling exhibit insulin resistance in skeletal 
muscle and WAT 
 
One of the major molecular components of the activated insulin signaling is 
the phosphorylation of AKT at Ser 473, resulting in AKT activation, thereby 
mediating insulin’s effects on glucose homeostasis further downstream. To 
get an insight in the alterations of glucose homeostasis and to further support 
the assumption of hepatic insulin resistance in IL-6RαL-KO mice, we analyzed 
the ability of insulin to stimulate AKT phosphorylation at Ser residue 473. 
Therefore we compared the protein levels of phosphorylated AKT in livers of 
IL-6RαL-KO and control mice by Western blot analysis during the basal state as 
well as the steady state phase of the euglycemic-hyperinsulinemic clamp 
study. In agreement with the assumption of a partial hepatic insulin 
resistance, the insulin stimulated AKT phosphorylation during the steady state 
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phase was significantly reduced in IL-6RαL-KO mice compared to control mice 
(Fig. 17 A and B).  
 
Fig. 17: Decreased insulin sensitivity in liver, skeletal muscle and WAT of IL-6RαL-KO 
mice 
(A) Representative Western blot analysis of insulin-stimulated AKT phosphorylation in liver 
from indicated mice at basal and steady state condition by using P-AKT and AKT antibody. 
(B) Results of Western blot analysis from (A) by quantification of AKT phosphorylation relative 
to AKT (n=6/genotype). (C) Tissue specific 14C glucose uptake during euglycemic 
hyperinsulinemic clamp study of IL-6RαL-KO and control mice (n= 12/genotype). (D) Western 
blot analysis of skeletal muscle from indicated mice at basal and steady state condition by 
using P-AKT and AKT antibody. (E) Quantification of Western blot analysis from (D) under 
both conditions (n=6/genotype). Showed data are means ± SEM. * p ≤ 0.05; ** p ≤ 0.01; 
*** p ≤ 0.001 versus controls. 
 
Other key insulin sensitive tissues, such as skeletal muscle and WAT are 
susceptible to develop local insulin resistance in the presence of increased 
caloric intake (170). 
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To elucidate the tissue specificity of insulin action and its contribution to the 
insulin resistance in IL-6RαL-KO mice, we additionally analyzed skeletal muscle 
and WAT for their insulin responsiveness. Strikingly, the insulin stimulated 
14C-glucose uptake during the euglycemic-hyperinsulinemic clamp was 
significantly reduced in skeletal muscle and WAT of IL-6RαL-KO mice 
compared to control mice (Fig. 17 C), indicating the development of systemic 
insulin resistance in IL-6RαL-KO mice compared to control mice. Consistent 
with these data, the ability of insulin to stimulate AKT phosphorylation in 
skeletal muscle was significantly reduced in IL-6RαL-KO mice compared to 
control mice (Fig. 17 D and E). 
 
Thus, the loss of hepatic IL-6 signaling has a moderate effect on the 
development of insulin resistance in the liver, but results in a pronounced 
impairment of insulin action in skeletal muscle and WAT. 
 
 
3.1.6 Increased inflammatory tone in IL-6RαL-KO mice 
 
Previous studies have revealed that an increased inflammatory tone, 
characterized by increased expression of inflammatory mediators, such as 
TNF-α and IL-6, correlates with the development of insulin resistance under 
obese conditions (60). To define the molecular basis of insulin resistance, 
both in liver and in skeletal muscle of IL-6RαL-KO mice, we next investigated 
the inflammatory tone in liver, skeletal muscle and WAT isolated from control 
and IL-6RαL-KO mice. Thus, the expression of key inflammatory cytokines IL-6, 
TNF-α, and the anti-inflammatory cytokine IL-10, were analyzed in liver and 
skeletal muscle isolated from control and IL-6RαL-KO mice at the basal and 
steady state phases of the euglycemic-hyperinsulinemic clamp study. While 
basal hepatic mRNA expression of IL-6, TNF-α, and IL-10 were comparable 
between both groups, the insulin-induced mRNA expression of IL-6, TNF-α, 
and IL-10 during the steady state phase of these genes was significantly 
increased in IL-6RαL-KO mice compared to control mice (Fig. 18 A). 
Additionally, the phosphorylation of inhibitor of NF-κB (IκBα) at Ser 32, which 
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is triggered by TNF-α stimulation, was clearly enhanced in livers of the 
IL-6RαL-KO mice compared to control mice during the steady state phase 
(Fig. 18 B and C). Nevertheless, phosphorylation of STAT-3 at Tyr residue 
705, which is mediated by stimulation with IL-6, was induced to a similar 
extend in livers of both groups (Fig. 18 B and C), indicated overlapping 
mechanisms of STAT-3 activation in the absence of IL-6Rα, presumably 
through IL-10 in response to in vivo insulin stimulation (Fig. 18 A). 
Fig. 18: Increased inflammation in livers of IL-6RαL-KO mice 
(A) Relative mRNA expression in livers of IL-6RαL-KO and control mice during basal and 
steady state phase of the clamp study (n=6/genotype). (B) Representative Western blot 
analysis of STAT-3 and IκBα activation in liver during basal and steady state condition by 
using the respective antibodies. (C) Quantification of Western blot analysis from (B) to 
determine STAT-3 and IκBα activation relative to AKT and IκBα under both conditions 
(n=6/genotype). Data represented as means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
 
Moreover, the mRNA expression of the inflammatory cytokines IL-6, TNF-α, 
and the anti-inflammatory cytokine IL-10, was also significantly enhanced in 
skeletal muscle of IL-6RαL-KO mice compared to control mice (Fig. 19 A). In 
consistency, increased TNF-α and IL-6 expression translates into the 
increased activation of IκBα in skeletal muscle of IL-6RαL-KO mice compared 
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to control mice during the steady state phase of the clamp (Fig. 19 B and C). 
The activation of STAT-3, as determined by Tyr 705 phosphorylation, was 
similar in skeletal muscle of both genotypes (Fig. 19 B and C). 
 
Fig. 19: IL-6RαL-KO mice exhibit elevated inflammatory state in skeletal muscle 
(A) Relative mRNA expression of inflammatory genes in skeletal muscle of IL-6RαL-KO and 
control mice during basal and steady state phase of the clamp study (n=6/genotype). 
(B) Representative Western blot of STAT-3 and IκBα phosphorylation in skeletal muscle 
during basal and steady state condition by using P-STAT-3, AKT, IκBα and P-IκBα 
antibodies. (C) Quantification of Western blot analysis from (B) to determine STAT-3 and 
IκBα activation relative to AKT and IκBα under both conditions (n=6/genotype). Displayed 
values are means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls.  
 
Furthermore, the insulin-induced mRNA expression of IL-6, TNF-α and IL-10 
was also significantly increased in WAT during the steady state phase 
compared to basal conditions in control and IL-6RαL-KO mice (Fig. 20 A). 
However, genotype specific differences were not observable.  
 
To finally address whether the increased inflammatory cytokine expression in 
the respective tissues also translates into alterations of circulating cytokine 
concentrations, we determined the circulating levels of IL-6, TNF-α and IL-10 
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in serum, isolated from both genotypes, by cytokine bead array (CBA) 
(Fig. 20 B). Under basal state serum levels of IL-6, TNF-α and IL-10 were 
found to be unaltered in both the genotypes. Although under steady state of 
the clamp, the serum concentrations of IL-6 and TNF-α were significantly 
elevated in both genotypes compared to basal state, this elevation was 
significantly more pronounced in IL-6RαL-KO mice compared to control mice.  
 
Fig. 20: IL-6RαL-KO mice exhibit enhanced systemic inflammation 
(A) Expression of IL-6, TNF-α and IL-10 mRNA in WAT of IL-6RαL-KO and control mice 
measured by quantitative RT-PCR (n=6/genotype). (B) Measured concentrations of IL-6, 
TNF-α and IL-10 in the sera of indicated mice under basal and steady state phase. 
Concentrations were detected using cytometric bead array (n=10/genotype). Data 
represented as means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
 
Thus, consistent with the increased mRNA expression of IL-10 in the steady 
state compared to the basal state during the clamp, circulating IL-10 levels 
were elevated in the steady state compared to the basal state. However IL-10 
levels were comparable between the control and IL-6RαL-KO mice in the 
steady state phase. 
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These data clearly indicate a role of hepatic IL-6 signaling in limiting liver and 
skeletal muscle inflammation by restricting the mRNA expression of the key 
inflammatory cytokines IL-6 and TNF-α and thereby, potentially protects from 
the development of local and systemic insulin resistance.  
 
 
3.1.7 Neutralization of TNF-α normalizes glucose homeostasis in IL-6RαL-KO 
mice  
 
To define the contribution of increased circulating TNF-α levels in mice 
lacking hepatic IL-6 signaling in the development of systemic insulin 
resistance and impaired glucose tolerance, the anti-TNF-α antiserum, that 
was previously described for its ability to diminish TNF-α signaling in mice 
(171), was administered i.p. to both genotypes. While the impaired glucose 
tolerance was similar in mice lacking hepatic IL-6 signaling before the 
administration (pre-treatment) of the anti-TNF-α antiserum (Fig. 14 A and 
Fig. 21 A), the administration of anti-TNF-α antiserum resulted in 
normalization of glucose homeostasis in IL-6RαL-KO mice during GTT 
(Fig. 21 B), without affecting glucose clearance in control mice. Taken 
together, these experiments clearly demonstrate that selectively elevated 
TNF-α levels lead to the impaired glucose tolerance in IL-6RαL-KO mice. 
 
 
Fig. 21: Ablation of TNF-α  lead to normalized glucose homeostasis in IL-6RαL-KO mice 
(A) Glucose tolerance test (GTT) monitored over 120 min of 9 weeks old IL-6RαL-KO and 
control mice before treatment with an anti-TNF-α antibody (n=10/genotype). (B) GTT of the 
same animals as in (A) after a 100 ml injection into the peritoneal cavity of an anti-TNF-α 
antiserum 1 h prior to the experiment (n=10/genotype). GTT was performed at week 10. 
Results represent means ± SEM. * p ≤ 0.05 versus controls. 
Results 
____________________________________________________________________________________________________________________________ 
 
 57 
Several studies have shown that IL-6 acts as negative feedback regulator of 
inflammatory signaling pathways in macrophages by decreasing expression of 
TNF-α (172).  
 
To investigate the involvement of liver resident macrophages, the Kupffer 
cells (KCs), in the development of systemic insulin resistance and impaired 
glucose homeostasis in IL-6RαL-KO mice, we performed glucose tolerance 
tests in IL-6RαL-KO and control mice after depletion of liver resident 
macrophages. The efficient depletion of Kupffer cells with clodronate 
liposomes was previously described (157) and further confirmed by staining of 
liver sections with the macrophage glycoprotein marker MAC-2 (Fig. 22 A 
and B).  
 
Fig. 22: Normalized glucose homeostasis in IL-6RαL-KO mice after depletion of Kupffer 
cells 
(A) Cryostat sections of livers from IL-6RαL-KO and control mice stained with MAC-2 for 
visualization of liver resident macrophages. (B) Representative MAC-2 stainings of liver 
sections from IL-6RαL-KO and control mice after 1 ml i.p. injection of clodronate liposomes 2 
days before the experiment. (C) Glucose tolerance test monitored over 120 min of IL-6RαL-KO 
and control mice at 11 weeks of age (n=10/genotype). (D) Glucose tolerance test of same 
animals as in (C) after injection of clodronate liposomes 2 days before the experiment 
(n=10/genotype). GTT were performed after a week regeneration period. Data represent 
means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
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Consistent with our previous findings (Fig. 14 A and Fig. 21 A), we observed 
impaired glucose tolerance in mice lacking hepatic IL-6 signaling before the 
administration of clodronate liposomes (Fig. 22 C). Strikingly, the depletion of 
KCs normalizes glucose homeostasis of IL-6RαL-KO mice to a similar level as 
in control mice during the GTT (Fig. 22 C and D). These results clearly 
indicate that the insulin-induced activation of KCs contributes to the 
development of impaired glucose tolerance in IL-6RαL-KO mice. 
 
In order to determine whether the treatment with clodronate liposomes 
affected the glucose stimulated insulin secretion, we next examined glucose 
stimulated insulin secretion (GSIS) in vivo of untreated and clodronate 
liposomes treated mice. The depletion of liver resident macrophages had no 
effect on insulin levels in control mice, but leads to an increased GSIS in 
IL-6RαL-KO mice compared to untreated mice (Fig. 23 A and B).  
 
Thus, these data indicate that the increased inflammatory state of IL-6RαL-KO 
mice not only leads to the development of peripheral insulin resistance but 
also inhibits a compensatory elevation of glucose stimulated insulin secretion. 
 
Fig. 23: Alterations of glucose stimulated insulin secretion after depletion of Kupffer 
cells in IL-6RαL-KO mice 
(A) Insulin levels during the GTT from Fig. 22 D, measured by ELISA (n=10/genotype). 
(B) Comparison of serum insulin concentrations of untreated (Fig. 14 A) or clodronate 
liposome (CL) treated (Fig. 22 A) IL-6RαL-KO and control mice. Insulin levels were compared 
at 0, 15, and 30min after the glucose injection (n=9-13/genotype and treatment). Displayed 
values are means ± SEM. * p ≤ 0.05 versus controls. 
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Taken together, the present results reveal a novel role of hepatic IL-6 
mediating crosstalk between liver parenchymal cells, i.e. hepatocytes, and 
liver resident macrophages to limit inflammation in the liver. The experiments 
clearly show, that the lack of IL-6 signaling in hepatocytes results in increased 
expression of TNF-α in Kupffer cells. The resulting systemic elevated level of 
TNF-α from Kupffer cells leads to the development of systemic insulin 
resistance in skeletal muscle and WAT as well as inhibiting glucose 
stimulated insulin secretion in pancreatic β-cells. 
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3.2 The effect of hepatic Myd88 signaltransduction on glucose 
homeostasis and HCC development 
 
Multiple lines of evidence indicate that also the innate immune response 
pathway is involved in the development of obesity-associated diabetes (173). 
Recent studies have linked innate immune response to the development of 
obesity, impaired energy homeostasis and obesity-associated insulin 
resistance (174, 175). Excess accumulation of fatty acids is a characteristic of 
metabolic disease and Toll-like receptor 4 (TLR4) is known to play a critical 
role in the activation of innate immune responses by the recognition of 
lipopolysaccharide. Several studies show that mice lacking TLR4 signaling 
are protected from the development of obesity and insulin resistance (113, 
176). Additionally, recent observations suggest an unexpected role for MyD88 
in preventing diabetes (177) and an important role of MyD88 in DEN-induced 
liver tumor development (118). Since obesity and cancer development are 
intimately connected, we decided to inactivate MyD88 specifically in 
hepatocytes to get insights into the molecular mechanisms underlying these 
diseases. 
 
 
3.2.1 Generation of MyD88L-KO mice 
 
To investigate the role of Toll-like receptor signaling in energy homeostasis 
and hepatocellular carcinoma (HCC) development, we generated mice lacking 
the major adaptor protein of TLR signaling, myeloid differentiation primary 
response gene 88 (MyD88), specifically in hepatocytes. Therefore we crossed 
mice in which exons 3 to 5 of the MyD88 gene were flanked by loxP sites 
(MyD88FL/FL mice (178)), with mice expressing the Cre recombinase under the 
control of the ALFP promoter (ALFP-Cre mice) (165). The resulting double-
heterozygous ALFP-Cre+/– MyD88FL/+ mice were further intercrossed to yield 
hepatocyte specific MyD88 knockout mice (MyD88L-KO mice). Littermates 
lacking the ALFP-Cre recombinase (MyD88FL/FL mice) were used as controls 
throughout the study (Fig. 24 A). 
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To verify the efficient and specific deletion of the loxP-flanked MyD88 allele 
exclusively in hepatocytes, we performed quantitative RT-PCR analysis of 
mRNA isolated from liver tissue of control and MyD88L-KO mice. The mRNA 
expression of hepatic MyD88 was significantly reduced in MyD88L-KO mice 
compared to control mice (Fig. 24 B).  
 
Fig. 24: Targeting strategy and ablation of MyD88 specific in the liver 
(A) Map of the wildtype (WT), the exons 3 to 5 loxP-flanked (FL) and the deleted (Δ) allele of 
MyD88. The deleted allele is shown after Cre loxP-mediated recombination. (B) Relative 
mRNA expression of MyD88 in livers of MyD88L-KO and control mice measured by quantitative 
RT-PCR (n=5-7/genotype). (C) Western blot analysis of protein lysates from MyD88L-KO and 
control mice for determination of MyD88 levels in the respective tissues. Protein content was 
determined by using MyD88 as well as Calnexin and β-actin antibodies for loading controls. 
(D) Liver weight of MyD88L-KO and control mice at week 20 (n=9-12/genotype). (E) Cryostat 
sections of livers from MyD88L-KO and control mice stained with H&E to analyze overall liver 
morphology. Data displayed are means ± SEM. *** p ≤ 0.001 versus controls. 
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Furthermore, Western blot analysis of liver, skeletal muscle and brain 
revealed selective deletion of MyD88 in liver of the MyD88L-KO mice, whereas 
the protein levels of MyD88 were unaltered in skeletal muscle and brain 
(Fig. 24 C). Moreover, the lack of hepatic MyD88 expression had no effect on 
liver weight as well as the integrity of the liver structure as determined by H&E 
staining of liver sections (Fig. 24 D and E).  
 
In summary, these experiments demonstrate an efficient and specific 
disruption of MyD88 in hepatocytes of MyD88L-KO mice without affecting liver 
morphology. 
 
 
3.2.2 Unaltered adiposity in mice lacking hepatic MyD88 signaling 
 
Recent studies revealed that obesity is characterized as a chronic low-grade 
inflammation, which in turn is causally linked to the development of insulin 
resistance (19, 179). Also, recent studies have suggested and linked innate 
immune responses to the development of obesity, impaired energy 
homeostasis and obesity-associated insulin resistance (174, 175). 
 
To determine whether hepatic MyD88 signaling affects adiposity, we analyzed 
body weight, epigonadal fat pad mass and body fat content in MyD88L-KO mice 
compared to control mice (Fig. 25). Although, control mice showed a 
consistent increase in body weight gain at older ages, no genotype-
dependent differences in body weight gain were observed between control 
and MyD88L-KO mice (Fig. 25 A). Similarly, epigonadfal fat pad mass (Fig. 25 
B) and total body fat content (Fig. 25 C) were unaltered between both 
genotypes. 
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Fig. 25: Similar bodyweight and body fat content between control and MyD88L-KO mice  
(A) Average bodyweight from week 3 to week 20 of MyD88L-KO and control mice 
(n=16-18/genotype). (B) Measured epigonaldal fat pad mass of indicated mice 
(n=16-18/genotype). (C) Total body fat content of both groups determined using nuclear 
magnetic resonance (n=16-18/genotype). Displayed values are means ± SEM. 
 
Usually, elevated plasma levels of triglycerides (TGs) as well as cholesterol 
are observed in obesity and are linked to the development of insulin 
resistance (3, 180, 181). To transport lipids, such as TGs and cholesterol, 
within the hydrophillic bloodstream, lipoproteins are used. The high-density 
lipoprotein (HDL) is one of the five major groups of lipoproteins and it is well 
known that obesity is frequently associated with low levels of serum 
HDL-cholesterol (182). 
 
Fig. 26: Unaltered cholesterol and lipid metabolism in MyD88L-KO mice 
(A) Plasma triglyceride levels of random fed MyD88L-KO and control mice at week 8 and 
week 16 (n=9-15/genotype). (B) Random fed blood cholesterol as well as HDL-cholesterol 
concentrations of 8 and 16 weeks old control and MyD88L-KO mice (n=9-15/genotype). 
Displayed results represent the mean ± SEM. * p ≤ 0.05; *** p ≤ 0.01 versus controls. 
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To investigate whether MyD88 signaling in the liver affects lipid 
concentrations or lipid transport, we analyzed blood plasma levels of TGs, 
cholesterol and HDL-cholesterol of control and MyD88L-KO mice (Fig. 26). 
Consistent with the unaltered adiposity observed between both genotypes, 
plasma levels of TGs, cholesterol and HDL-cholesterol were similar in control 
and MyD88L-KO mice, although plasma HDL-cholesterol levels were elevated 
in older control and MyD88L-KO mice compared to younger mice. 
 
Taken together, these results imply hepatic MyD88 signaling as non-essential 
in maintaining bodyweight or lipid metabolism. 
 
 
3.2.3 Glucose homeostasis and insulin sensitivity is unaltered in MyD88L-KO 
mice 
 
The role of TLR signaling, especially through the adaptor protein MyD88, in 
preventing the development of insulin resistance has been defined in earlier 
studies in brain, skeletal muscle, WAT and liver (177, 178, 183). However, the 
role of MyD88 dependent signaling in hepatocytes in maintaining insulin 
sensitivity is largely undefined. To evaluate the molecular mechanisms linking 
hepatic MyD88 signaling to glucose homeostasis and insulin sensitivity, we 
investigated the physiological role of MyD88 in the liver. Therefore, random 
fed blood glucose levels of control and MyD88L-KO mice were determined. As 
shown in Figure 27 A, no obvious differences were apparent at week 8 of age 
as well as at week 16 of age between control and MyD88L-KO mice. In 
consistency to the unchanged blood glucose levels, random fed circulating 
insulin concentrations were also unaltered between control and MyD88L-KO 
mice (Fig. 27 B).  
 
Moreover, glucose homeostasis and insulin sensitivity in control and 
MyD88L-KO mice were further investigated by GTT and ITT at the age of 12 
and 13 weeks, respectively. When challenged with glucose during GTT, 
MyD88L-KO and control mice exhibit a similar glucose tolerance and a similar 
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rate of glucose clearance from the blood (Fig. 27 C). In line with unaltered 
glucose homeostasis, control and MyD88L-KO mice exhibit unaltered insulin 
sensitivity, when challenged with an intraperitoneal injection of insulin in ITTs 
(Fig. 27 D). 
 
Fig. 27: Unaltered glucose homeostasis and insulin sensitivity in MyD88L-KO mice 
(A) Blood glucose levels of random fed MyD88L-KO and control mice at week 8 and week 16 
(n=16/genotype). (B) Random fed blood insulin concentrations of 8 and 16 weeks old as 
determined by ELISA (n=10/genotype). (C) Glucose tolerance test monitored over 120 min of 
12 weeks old MyD88L-KO and control mice (n=16/genotype). (D) Insulin tolerance test 
performed on both groups at the age of 13 weeks (n=16/genotype). The results represent the 
mean ± SEM. 
 
Taken together, these results indicate that hepatic MyD88 signaling provides 
no profound effect on glucose homeostasis and insulin sensitivity.  
 
 
3.2.4 MyD88L-KO mice exhibit reduced DEN-induced hepatocarcinogenesis 
 
Already in 1863, Rudolf Virchow found first indications for the connection 
between inflammation and cancer, and many studies have supported this 
assumption over the last decades (184, 185). Additionally, the development of 
hepatocellular carcinoma (HCC) has been linked with the persistent hepatic 
inflammation through factors that lead to chronic hepatic injury (106). In 
experimental studies, the chemical diethylnitrosamine (DEN) is widely used to 
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induce chronic liver injury, which ultimately leads to the development of HCC 
(160).  
 
That systemic deletion of MyD88 in mice leads to decreased DEN-induced 
tumor development was demonstrated previously (118). However, the cell 
type specific contribution of MyD88 signaling could not be addressed due to 
the use of conventional KO mice. Thus, we investigated the role of hepatic 
MyD88 signaling in the development of chemically induced HCC formation. 
Hence, we treated control and MyD88L-KO mice with the HCC inducer DEN at 
day 15 after birth and analyzed the DEN-induced HCC development in control 
and MyD88L-KO mice after 8 moths of age. 
 
The alanine transaminase (ALT) and aspartate transaminase (AST) are 
enzymes, which are predominantly found in liver. Upon tissue damage, the 
activity as well as protein concentration of these enzymes increases within the 
liver. The blood serum concentrations are sensitive to toxic liver injury, 
because only elevated levels of ALT and AST leads to the translocation into 
the bloodstream (186, 187). Therefore, we examined the blood serum levels 
of ALT and AST in MyD88L-KO and control mice, either untreated as well as 
DEN-treated. Although ALT levels were significantly increased after DEN 
administration in both genotypes, no significant difference was detected 
between MyD88L-KO and control mice (Fig. 28 A). This was consistent with 
higher AST levels in the blood of DEN treated MyD88L-KO and control mice, 
with no alterations between both genotypes (Fig. 28 B). The De-Ritis-Quotient 
(AST/ALT) (188) gives additional information about liver damage, since 
hepatic injury leads to stronger elevation of AST compared to ALT 
concentrations, resulting in a higher De-Ritis-Quotient. While a significantly 
elevated De-Ritis-Quotient was observed in control mice after DEN injection 
compared to untreated control mice, the MyD88L-KO mice show only a slightly 
increased De-Ritis-Quotient (Fig. 28 C). However, this elevation did not reach 
statistical significance. Together, these results indicate a compromised 
potential of DEN to induce hepatic injury in MyD88L-KO mice compared to 
control mice and thereby leading to reduced DEN-induced liver damage. 
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Fig. 28: Reduced DEN-induced liver damage in MyD88L-KO mice 
(A-B) Measured (A) ALT and (B) AST levels in sera of untreated and with 25 mg/kg DEN 
treated MyD88L-KO and control mice at 12-16 weeks of age (n=7-12/genotype). (C) Calculated 
De-Ritis-Quotient of (A) and (B). The De-Ritis-Quotient is calculated by dividing AST through 
ALT. Displayed values are means ± SEM. * p ≤ 0.05 versus controls. 
 
Strikingly, DEN-induced tumor formation in livers of MyD88L-KO and control 
mice (Fig. 29) revealed an overall reduced number of hepatocellular 
carcinomas in MyD88L-KO mice compared to control mice (Fig. 29 C). 
Additionally, the reduction in number of tumor formation was also 
accompanied with significantly decreased HCC sizes (Fig. 29 D), implying a 
prominent role of hepatic MyD88 signaling in regulating DEN-induced HCC 
formation.  
 
To investigate whether proliferation in the liver is affected in the absence of 
hepatic MyD88 and thus leads to decreased HCC development, the 
proliferative status in tumor livers of both genotypes was determined. Ki-67 
protein is strongly associated with cell proliferation and therefore a prominent 
cellular marker for proliferation (189). To examine Ki-67 abundance in 
tumorgenesis, we performed Ki-67 stainings of DEN treated livers of control 
and MyD88L-KO mice (Fig. 29 F). However, no genotype-dependent 
differences of proliferative cells in tumor foci of the liver were observed 
between control and MyD88L-KO mice (Fig. 29 G). 
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Fig. 29: Lower DEN-induced HCC incidence in MyD88L-KO mice 
(A-B) Representative livers of either (A) untreated or (B) 25 mg/kg DEN treated 8 months old 
MyD88L-KO and control mice. (C) Quantification of macroscopic tumor multiplicity, determined 
by visual inspection in DEN-injected 8 month old control and MyD88L-KO mice 
(n=10-12/genotype). (D) Enumeration of tumor number < 2 mm, 2-5mm and > 5 mm from (C), 
as determined by visual inspection (n=10-12/genotype). (E-F) Cryostat sections of livers from 
DEN treated MyD88L-KO and control mice stained with (E) H&E for tumor morphology and (F) 
with Ki-67 (red) to determine proliferative cells as well as DAPI (blue) for total cell number of 
MyD88L-KO and control mice. (G) Quantification of (F) Ki-67 positive cells relative to total cell 
number (n=4/genotype). Data represent means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
 
 
 
Overall, these findings indicate that the loss of hepatic MyD88 signaling leads 
to reduced DEN-induced liver damage and to a lower HCC incidence coupled 
with reduced DEN-induced tumor size. This reduction of tumor incidence was 
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not due to decreased proliferation in tumor foci of livers of MyD88L-KO mice 
compared to control mice. 
 
 
3.2.5 Reduced expression of macrophage markers in HCC of mice lacking 
hepatic MyD88 signaling  
 
Inflammation plays a major role in the response to damaged cells. It is 
characterized by infiltrating immune cells, such as macrophages into 
damaged tissues, where it elicits an inflammatory response characterized by 
expression and secretion of the key inflammatory cytokines IL-6, TNF-α and 
IL-1β. In the liver, mainly liver resident macrophages (Kupffer cells) are 
responsible for eliciting this inflammatory response. Upon activation by 
different stimuli in the blood, which is passed through a network of hepatic 
sinusoids, the Kupffer cells release numerous cytokines, such as IL-6, TNF-α 
and IL-1β as well as certain chemokines, such as monocyte chemo-attractant 
protein 1 (MCP-1), which initiates the recruitment of additional immune cells to 
the liver (190, 191). 
 
Since macrophages are the key initiator of hepatic inflammation in response 
to liver damage, we determined the macrophage content of the liver after 
DEN-induced HCC. Therefore we analyzed the expression of macrophage 
markers Integrin-α-M (ITGAM), Integrin-α-X (ITGAX), CD-68, F4/80 and 
MAC-2 in liver lysates of untreated and DEN-injected mice.  
 
The mRNA expression of Integrin-α-M (ITGAM) and Integrin-α-X (ITGAX), 
expressed in granulocytes and monocytes (192, 193) was unchanged before 
and after DEN treatment in control and MyD88L-KO mice. Although, the 
injection of DEN resulted in increased CD-68 mRNA expression in the livers 
of both genotypes, the CD-68 mRNA expression was unaltered between 
control and MyD88L-KO mice (Fig. 30 A). In addition, while hepatic mRNA 
expression of the key macrophage markers F4/80 and MAC-2 (194, 195) 
were induced by DEN in control mice, the mRNA expression of F4/80 and 
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MAC-2 was blunted in livers of DEN MyD88L-KO mice (Fig. 30 B), indicating 
reduced DEN-induced macrophage migration in livers of mice lacking hepatic 
MyD88 signaling. 
 
Fig. 30: MyD88L-KO mice show reduced macrophage marker expression in the liver 
(A-B) Relative mRNA expression of indicated (A) granulocyte and monocyte markers as well 
as (B) specific macrophage markers in livers of untreated and DEN treated mice 
(n=6/genotype). Data were obtained by quantitative RT-PCR of liver lysates. Displayed 
values are means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
 
To investigate whether the reduced macrophage marker mRNA expression 
after DEN treatment in livers of MyD88L-KO mice results from reduced mRNA 
expression of key chemo-attractants, MCP-1, RANTES, MCP-3, or the 
macrophage inflammatory proteins (MIP) MIP-1α and MIP-1β, we measured 
mRNA expression of these chemokines in livers of untreated and 
DEN-injected control and MyD88L-KO mice. While hepatic mRNA expression of 
MCP-1, RANTES and MCP-3 was unaltered between non-treated and DEN 
treated control and MyD88L-KO mice, mRNA expression of MIP-1α and MIP-1β 
increased significantly in liver of both genotypes upon DEN treatment. 
Nevertheless, no genotype-dependent alterations were detectable in MIP-1α 
and MIP-1β mRNA expression between control and MyD88L-KO mice, even in 
the untreated state (Fig. 31 A and B). 
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Fig. 31: Unaltered mRNA expression of chemokines between control and MyD88L-KO 
mice 
(A-B) Relative mRNA expression of indicated (A) MCP-1, RANTES and MCP-3 as well as (B) 
MIP-1α and MIP-1β in livers of untreated and DEN treated mice (n=6/genotype), determined 
by quantitative RT-PCR. Data are means ± SEM. * p ≤ 0.05 versus controls. 
 
 
3.2.6 The mRNA expression of LIF in HCC is mediated by hepatic MyD88 
 
The inflammatory process is characterized by elevated pro-inflammatory 
cytokine expression, such as IL-6, IL-1β and leukemia inhibitory factor (LIF). 
During the development of HCC, not only pro-inflammatory cytokines are 
expressed, but also anti-inflammatory cytokines, such as IL-10, are increased 
(196). Several chemokines, e.g. IL-6, LIF and IL-10, induce the activation of 
STAT-3 by phosphorylation at Tyr 705. Persistently activated STAT-3 
increases tumour cell proliferation, survival and invasion by promoting pro-
oncogenic inflammatory pathways (197). MyD88 is required for IL-6 induction 
by necrotic debris and for DEN-induced production of IL-6 in vivo (118). To 
define the role of hepatic MyD88 in this context, we analyzed hepatic 
expression of the pro-inflammatory cytokines IL-6 and LIF, as well as the anti-
inflammatory cytokine IL-10 before and after DEN treatment. Interestingly, 
mRNA expression of IL-6 in the liver was neither induced by DEN, nor 
differentially expressed between control and MyD88L-KO mice, indicating a 
minor role of this cytokine in the development of DEN induced HCC in our 
study (Fig. 32 A). Strikingly, the mRNA expression of the IL-6 type cytokine 
LIF was strongly induced in livers of DEN treated control mice, whereas this 
increased hepatic mRNA expression was significantly blunted in MyD88L-KO 
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mice. The same was true for the anti-inflammatory cytokine IL-10, which is 
known to be elevated in HCC (196). Although the mRNA expression was 
elevated in liver of chemically induced HCC compared to untreated control 
mice, the hepatic mRNA expression of IL-10 in MyD88L-KO mice was unaltered 
between untreated and DEN treated livers (Fig. 32 A). To investigate whether 
this increased mRNA expression of LIF and IL-10 translated in elevated 
activation of STAT-3 in control mice, we further analyzed the phosphorylation 
status of STAT-3 at Tyr residue 705 (Fig. 32 B and C).  
 
Fig. 32: Elevated mRNA expression of LIF in MyD88L-KO mice compared to control mice  
(A) Relative mRNA expression of IL-6, LIF and IL-10 in livers of both genotypes either 
untreated or DEN treated. The mRNA expression was determined by quantitative RT-PCR 
(n=6/genotype).  (B) Western blot analysis of liver lysates from untreated and DEN treated 
control and MyD88L-KO mice. Protein content was determined by using P-STAT-3 and 
Calnexin antibodies. (C) Quantification of Western blot analysis from (B) to determine the 
phosphorylation of STAT-3 at Tyr residue 705 relative to Calnexin (n=5-6/genotype). 
(D) EMSA of nuclear protein extracts isolated from livers of control and MyD88L-KO mice either 
untreated or DEN treated. The DNA-binding capacity of STAT-3 was determined by using 
radioactively labeled probes of STAT-3 as well as specific protein 1 (SP-1), which served as 
loading control. Data are means ± SEM. * p ≤ 0.05; ** p ≤ 0.01 versus controls. 
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Moreover, the DNA-binding capacity of STAT-3 was determined by an 
electrophoretic mobility shift assay (EMSA) using nuclear extracts from 
untreated as well as DEN treated control and MyD88L-KO mice. Although LIF 
and IL-10 mRNA expression as well as the phosphorylation of STAT-3 was 
clearly elevated in control mice, the DNA-binding capacity of STAT-3 was 
unaltered between untreated and DEN treated control mice. Additionally, the 
binding capacity and the phosphorylation of STAT-3 were also unaltered 
between both genotypes (Fig. 32 D). 
 
Furthermore, we investigated the effects of acute DEN treatment on IL-6 
signaling to get insight in early stages of liver damage. Therefore we analyzed 
hepatic mRNA expression of IL-6 as well as STAT-3 activation of untreated 
and acute DEN treated control and MyD88L-KO mice (Fig. 33). This analysis 
revealed no genotype-dependent differences in IL-6 mRNA expression, 
neither in untreated or 4 h acute DEN-treated control and MyD88L-KO mice 
(Fig. 33 A). Consistent with the observations in tumor livers, acute DEN 
treatment lead to increased STAT-3 activation in control and MyD88L-KO mice, 
although this activation was similar between both genotypes (Fig. 33 B). 
 
Fig. 33: Unaltered IL-6 signaling in MyD88L-KO mice compared to control mice upon 
acute DEN treatment 
(A) Relative mRNA expression of IL-6 in livers of both genotypes either untreated or 4 h acute 
DEN-treated. The mRNA expression was determined by quantitative RT-PCR 
(n=6/genotype).  (B) Western blot analysis of liver lysates from untreated and 4 h as well as 
48 h acute DEN-treated control and MyD88L-KO mice. Protein content was determined by 
using P-STAT-3 and Calnexin antibodies. Data are means ± SEM. 
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Taken together, hepatic MyD88 is important in mediating LIF as well as IL-10 
mRNA expression in DEN-induced HCC, since MyD88L-KO mice show no 
induction of either LIF or IL-10 mRNA expression in DEN-induced HCC, 
whereas IL-6 mRNA expression in the liver is not dependent on hepatic 
MyD88. Additionally, the similar IL-6 mRNA expression in both genotypes and 
treatments could be responsible for unaltered activation and DNA-binding 
capacity of STAT-3 in these conditions.  
 
 
3.2.7 Reduced NF-κB activation in DEN-induced HCC of MyD88L-KO mice  
 
A major link between inflammation and cancer is mediated by NF-κB 
transcription factors. While constitutive NF-κB activation has been observed in 
tumor tissues (198), hepatocyte specific disruption of IKKβ in mice shows 
hypersusceptibility to DEN-induced hepatocarcinogenesis (141).  
 
Fig. 34: MyD88L-KO mice exhibit reduced p65 activation upon DEN treatment 
(A) Representativ Western blot analysis of liver lysates from untreated as well as DEN treated 
control and MyD88L-KO mice. Protein content was determined by using P-p65, p65 and 
Calnexin antibodies. (B) Quantification of Western blot analysis from (A) to determine the 
phosphorylated status of p65 relative to unphosphorylated p65 (n=6/genotype). Data are 
means ± SEM. ** p ≤ 0.01 versus controls. 
 
Since IKKβ is an activator of NF-κB in response to pro-inflammatory stimuli as 
well as TLR signaling, we were interested in the activation status of hepatic 
NF-κB in DEN-induced HCC of control and MyD88L-KO mice. Therefore we 
determined the phosphorylation of p65, a part of the NF-κB complex, at Ser 
residue 536. Hepatic p65 was neither activated in DEN treated livers of 
control mice nor in livers of MyD88L-KO mice compared to untreated mice. 
Results 
____________________________________________________________________________________________________________________________ 
 
 75 
Nevertheless, significant decreased activation of hepatic p65 was observed in 
DEN-induced HCC of MyD88L-KO mice compared to control mice (Fig. 34 A 
and B), indicating a hypersusceptibility to DEN-induced hepatocarcinogenesis 
of MyD88L-KO mice. 
 
It was previously shown that reduced NF-κB activation due to hepatocyte 
specific IKKβ-deficiency not only increases DEN-induced liver cancer, but 
also leads to elevated JNK activation. Conventional ablation of JNK in 
IKKβ-deficient mice reverses the increased susceptibility to HCC upon 
DEN-treatment (141).  
 
 
3.2.8 MyD88L-KO mice exhibit reduced hepatic JNK activation in DEN-induced 
HCC 
 
The TLR signaling cascade is known to activate JNK as well as other MAPKs, 
such as ERK and p38. They are major components of pathways controlling 
differentiation, proliferation and apoptosis, and transduce signaling upon 
stimulation of cytokines, growth factors, and stress signals (123). Deregulation 
of MAPKs in various types of tumors, including HCC are also described (124). 
Whereas elevated levels of active ERK and JNK1 were found in 
hepatocellular carcinoma (126, 140, 141), p38 exhibits an important role in 
suppressing HCC tumorgenesis (135). Since TLR signaling leads to the 
activation of MAPKs by TAK1 (199), we were interested in the role of TLR 
mediated MAPK signaling in DEN-induced HCC. To investigate the role of 
hepatic MyD88 in activation of MAPKs during HCC development, we analyzed 
the phosphorylation status of JNK, ERK1/2 and p38 by Western blot analysis. 
Nevertheless, phosphorylation of ERK1/2 at Thr 202 and Tyr 204 as well as 
phosphorylation of p38 at Thr 180 and Tyr 182 were completely unaltered 
between treatment and genotypes, indicating a minor role of active ERK1/2 
and p38 in DEN-induced HCC (Fig. 35 A and E). However, partly activated 
MAPK signaling was induced in liver of control mice after DEN treatment. In 
contrast to ERK1/2 and p38 activation, the phosphorylation of hepatic JNK at 
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Thr 183 and Tyr 185 was significantly increased in DEN treated control mice 
compared to untreated control mice. However, this activation was significantly 
blunted in MyD88L-KO mice, indicating an important role of hepatic MyD88 in 
driving activation of JNK (Fig. 35 C). 
 
 
Fig. 35: Reduced JNK activation in HCC of MyD88L-KO mice compared to control mice 
(A), (C) and (E) Representative Western blots of livers from both genotypes as well as 
untreated and DEN treated mice. Protein content was determined by using indicated 
antibodies. (B), (D) and (F) Quantification of Western blot analysis from (A), (C) and (E) to 
determine the phosphorylated status of ERK1/2, JNK and p38 relative to unphosphorylated 
ERK1/2, JNK and p38α, respectively (n=6/genotype). Data represent means ± SEM. 
** p ≤ 0.01 versus controls. 
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To investigate whether MAPK signaling contributes to the early stages of HCC 
development, we determined the phosphorylation status of JNK, ERK1/2 and 
p38 of untreated and 4 h acute DEN treated animals by Western blot analysis 
(Fig. 36). Consistent with the observed unaltered phosphorylation of ERK1/2 
and p38 in DEN-induced HCC, these phosphorylations were also unaltered 
between treatment and genotypes, indicating a minor role of active ERK1/2 
and p38 in the early stages of HCC development (Fig. 36 A and B). In 
contrast to the observed reduction of active JNK in DEN-induced HCC, the 
phosphorylation of JNK was similarily elevated in 4 h acute DEN treated 
animals compared to untreated animals of both genotypes (Fig. 36 C), 
indicating a MyD88 independent JNK activation at the early phase of tumor 
development. 
 
Fig. 36: Unaltered MAPK signaling in MyD88L-KO mice upon acute DEN treatment 
(A-C) Western blot analysis of liver lysates from both genotypes (untreated and 4 h acute 
DEN treated mice). Protein content was determined by using indicated antibodies. Data 
represent means ± SEM. ** p ≤ 0.01 versus controls. 
 
The activation of JNK has been implicated in both, the promotion as well as 
inhibition of cell death, depending on the stimulus and cell type (200). It was 
shown that cellular stress leads to JNK activation mediated by tumor necrosis 
factor receptor 1 (TNFR1), which is the main receptor that induces 
TNF-induced cellular events such as cell proliferation, differentiation and 
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apoptosis (201, 202). Additionally, DNA damage-inducible transcript 3 (Ddit3 
also known as CHOP) is essential for sensitizing hepatoma cells to 
TRAIL-induced apoptosis (203) and is known to be activated by the MAPK 
signaling cascade. Other apoptotic related genes, such as B-cell lymphoma 2 
(Bcl-2), Bcl-2-like protein 11 (Bim) and Bcl-2–associated X protein (Bax), are 
known to be transcriptionally regulated by p38 signaling and play an important 
role in tumor development (204, 205). Since the loss of sensitivity to apoptosis 
is a hallmark of cancer, we analyzed the mRNA expression of the pro-
apoptotic mediators TNF-α, TNFR1, CHOP, Bcl-2 and Bim in untreated as 
well as DEN-treated livers of control and MyD88L-KO mice. Interestingly, while 
mRNA expression of TNF-α in the liver was unaltered in both genotypes and 
conditions, hepatic TNFR1 and CHOP mRNA expression was significantly 
increased in DEN-treated control mice compared to untreated control mice. 
Although untreated MyD88L-KO mice show unaltered mRNA expression of 
TNFR1 and CHOP compared to untreated control mice, the DEN-induced 
increase in mRNA expression was blunted in MyD88L-KO mice compared to 
controls (Fig. 37 A). Consistent with unaltered p38 activation, the hepatic 
mRNA expression of Bcl-2, Bim and Bax was neither unaltered in untreated 
control and MyD88L-KO mice, nor induced by DEN in both genotypes 
(Fig. 37 B). 
 
Fig. 37: MyD88L-KO mice exhibit decreased pro-apoptotic marker expression  
(A-B) Relative mRNA expression of indicated genes in livers of control and MyD88L-KO mice, 
determined by quantitative RT-PCR (n=6/genotype). Quantitative RT-PCR was performed on 
mRNA isolated from livers of untreated as well as DEN treated mice. Data are means ± SEM. 
* p ≤ 0.05; ** p ≤ 0.01 versus controls. 
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Taken together, these data indicate that hepatic MyD88 signaling is essential 
for the activation of JNK in DEN-induced HCC, whereas ERK1/2 and p38 
activation is MyD88 independent in tumor livers. Additionally, the decreased 
activation of JNK is possibly due to reduced mRNA expression of TNFR, 
which presumably translates into impaired induction of CHOP mRNA 
expression. Since ERK1/2 and p38 activation is unaltered between both 
genotypes, the reduction of CHOP mRNA expression upon DEN treatment in 
MyD88L-KO mice does not reach significance when compared to control mice. 
However, during the early phase of HCC development upon 4 h acute DEN 
treatment, JNK activation was similar between MyD88L-KO and control mice. 
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4. Discussion 
 
 
Over the last decades, chronic inflammation has been linked to the 
development of various diseases, such as obesity-associated insulin 
resistance and cancer. However, the underlying mechanisms through which 
chronic inflammation induces these disorders have not been fully elucidated 
yet and just begin to emerge. It has been reported earlier that under 
conditions of obesity, the expression of the pro-inflammatory cytokine TNF-α 
in adipose tissue is increased, thereby leading to the development of insulin 
resistance, whereas neutralisation of TNF-α in these mice leads to improved 
insulin sensitivity (60). Additional work has reveald, that obesity represents a 
state of chronic, low-grade inflammation, characterized by elevated plasma 
concentrations of inflammation-associated factors, such as TNF-α, 
Interleukin-6 (IL-6) and Interleukin-1β (IL-1β), which in turn may contribute to 
the development of insulin resistance (65-68). These cytokines are released 
from inflamed tissue during the course of obesity, such as WAT and liver. On 
the other hand, increased number of immune cells in neoplastic tissue might 
be an indicator for the connection between inflammation and cancer (103).  
 
The Toll-like receptor (TLR) signaling pathway, a classic signaling cascade in 
innate immunity, as well as the TLR signaling target proteins, NF-κB and JNK, 
are crucial regulators for the production of cytokines and are associated with 
tumor promotion and the development of obesity-associated insulin resistance 
(118, 140, 149). However, the role of hepatocyte specific TLR signaling in 
inflammatiory-associated diseases, such as obesity-associated insulin 
resistance and hepatocellular carcinoma, were not elucidated. 
 
In this study, the conditional gene targeting has been applied to hepatocyte 
specific disruption of either the key receptor of mediating IL-6 signaling or TLR 
signaling to examine the effect of inflammatory mediators in the liver on the 
development of obesity-associated insulin resistance and chemically induced 
hepatocellular carcinoma, respectively. To this end, IL-6RαFL/FL mice were 
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crossed with ALFP-Cre mice and offspring carrying the homozygous 
loxP-flanked allele and the Cre transgene were used to determine the effect of 
hepatic IL-6 signaling on glucose homeostasis. In order to specifically 
inactivate TLR signaling in hepatocytes, mice carrying a conditional allele for 
the essential adaptor molecule MyD88 were crossed to ALFP-Cre mice and 
phenotypically characterized for the development of insulin resistance and 
HCC pathogenesis. 
 
 
4.1 The ALFP-Cre transgene mediates specific inactivation of the 
loxP-flanked IL-6Rα or MyD88 alleles in hepatocytes 
 
The Cre-loxP system is a site-specific recombinase system, used to 
manipulate genomic DNA sequences in mammals and other species by 
inversion, excision or translocation of loxP-modified DNA sequences (206, 
207). The tissue specific, Cre-mediated recombination is performed using a 
cell-specific promotor driving the Cre expression. Since expression of the Cre 
recombinase under control of the albumin promotor/α-fetoprotein enhancer 
(ALFP), is restricted to hepatocytes (165), mice harboring the transgenic 
ALFP-Cre allele were used in this study to delete either IL-6Rα or MyD88 
selectively in hepatocytes.  
 
The function of IL-6 in the development of obesity-induced insulin resistance 
is controversially discussed (77). In order to address the specific role of 
inflammatory signaling downstream of the IL-6Rα in hepatocytes on insulin 
action and glucose homeostasis in vivo, the IL-6Rα was specifically ablated in 
hepatocytes. For this, mice bearing the loxP-flanked IL-6Rα allele were 
crossed with mice harboring the transgenic ALFP-Cre allele to obtain 
hepatocyte specific disruption of the IL-6Rα. We verified the selective and 
efficient deletion of the IL-6Rα allele in hepatocytes of IL-6RαL-KO mice on the 
genomic DNA and mRNA levels. Strikingly, IL-6Rα deficiency in hepatocytes 
did not affect liver weight, histomorphological liver structure as well as 
circulating sIL-6Rα levels. 
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On the other hand, to investigate the role of TLR signaling specifically in the 
liver, we created mice lacking hepatic MyD88 by crossing MyD88FL/FL and 
ALFP-Cre mice. Specific ablation of MyD88 in hepatocytes of MyD88L-KO mice 
was verified on mRNA and protein levels. These results indicate that the 
ALFP-Cre transgene excise loxP-flanked MyD88 specifically and efficiently in 
hepatocytes, without affecting liver weight and liver morphology.  
 
Taken together, the IL-6RαL-KO mice as well as MyD88L-KO mice were 
successfully generated to study the hepatic role of either pathway in the 
development of obesity-associated diseases.  
 
 
4.2 Hepatocyte specific disruption of the IL-6Rα impairs glucose 
homeostasis and insulin sensitivity 
 
Currently, the role of IL-6 signaling in energy homeostasis, obesity and insulin 
resistance is controversially debated. While systemic lack of IL-6 signaling 
leads to development of mature onset obesity (167), mice lacking hepatic IL-6 
signaling exhibit no alterations in energy homeostasis and body weight gain. 
Moreover, the circulating leptin levels were comparable between control and 
IL-6RαL-KO groups of mice, which is accompanied with equal amount of food 
being consumed in both, IL-6RαL-KO and control mice. Although these data 
indicate that hepatic IL-6 signaling is not essential for maintaining energy 
homeostasis, the loss of hepatic IL-6 signaling impairs glucose homeostasis 
as IL-6RαL-KO mice showed impaired glucose clearance during glucose 
tolerance tests. These experiments are in line with observations that IL-6 
treatment increases glucose tolerance in rats (84).  
 
Hepatic insulin resistance leads to the impaired suppression of hepatic 
glucose production under feeding conditions and thus exhibit a crucial impact 
on the impairment of whole body glucose metabolism (208). IL-6 signaling 
plays an important role in the development of hepatic insulin resistance during 
obesity (80, 209). To investigate the role of hepatic IL-6 signaling in the 
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development of insulin resistance in control and IL-6RαL-KO mice, 
euglycemic-hyperinsulinemic clamp studies were performed and 
insulin-mediated phosphorylation of AKT in the liver was assessed. During 
euglycemic-hyperinsulinemic clamp, insulin’s ability to mediate AKT activation 
was blunted in IL-6RαL-KO mice compared to control mice, revealing the 
development of hepatic insulin resistance in these mice. This indicates that 
hepatic IL-6 signaling is essential for the maintainance of hepatic insulin 
sensitivity. However, the suppression of hepatic glucose production was 
unchanged between both genotypes, presumably due to the fact, that hepatic 
glucose output does not only represents glucose production, but also hepatic 
glucose usage, such as glycogenolysis and gluconeogenesis. Since glucose 
cycling between glucose and G6P are important mechanisms in regulating 
glucose homeostasis, we determined the levels of two prominent enzymes, 
the G6Pase and the GK, that exhibit key roles in regulation of these 
processes (55, 57). Interestingly, IL-6 is able to downregulate G6Pase 
expression and thereby reducing hepatic glucose output (85). Here, we 
confirm the inhibitory action of IL-6 on insulin-mediated suppression of 
G6Pase. Although, hepatic G6Pase mRNA expression in IL-6RαL-KO mice is 
largely suppressed during hyperinsulinemic-euglycemic clamps compared to 
the fasted state, G6Pase mRNA and protein expression are significantly 
increased at the steady state phase of IL-6RαL-KO mice compared to control 
mice. In contrast, insulin’s ability to increase mRNA expression of the G6Pase 
counteracting glucokinase was significantly enhanced in IL-6RαL-KO mice 
compared to control mice, thus promoting glycogen synthesis. This in turn, 
explains the minor net effect on total hepatic glucose output in IL-6RαL-KO 
mice. Taken together, the study provides in vivo evidence for partly 
counteracting effects of IL-6 in hepatic glucose metabolism.  
 
Other key insulin sensitive tissues, such as skeletal muscle and WAT, are 
susceptible to the development of local insulin resistance in presence of 
increased caloric intake, thus leading to decreasesd stimulation of glucose 
disposal and ultimately resulting in the development of impaired glucose 
homeostasis (170). IL-6 action increases muscle insulin sensitivity (210) and 
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IL-6 levels are elevated during exercise (211), a situation in which glucose 
uptake is cruicial for energy supply of skeletal muscle. The consequence of 
blunted hepatic IL-6 signaling was assessed on muscle insulin sensitivity. To 
gain insight in the insulin responsiveness in skeletal muscle and WAT, the 
insulin stimulated glucose uptake was determined during 
hyperinsulinemic-euglycemic clamp study. The results revealed a significantly 
reduced glucose uptake in skeletal muscle and WAT of IL-6RαL-KO mice 
compared to control mice. Moreover, the efficiency of insulin to stimulate AKT 
phosphorylation in skeletal muscle was significantly reduced in IL-6RαL-KO 
mice compared to control mice, implying the development of systemic insulin 
resistance in IL-6RαL-KO mice compared to control mice. Consistent with these 
findings, insulin’s ability to lower blood glucose levels during insulin tolerance 
tests was significantly reduced in IL-6RαL-KO mice compared to control mice.  
 
Earlier observations of increased systemic insulin sensitivity and improved 
glucose tolerance upon IL-6 injection in mice, (84) as well as our findings, 
support the notion that IL-6 signaling is essential in protecting from the 
development of obesity-associated insulin resistance.  
 
 
4.3 Crosstalk between hepatocytes and Kupffer cells through hepatic 
IL-6 signaling controls the inflammatory tone 
 
We demonstrate that during euglycemic-hyperinsulinemic clamp studies, IL-6 
expression is increased in liver, skeletal muscle and WAT, resulting in 
increased circulating IL-6 concentrations. Additionally, increased expression 
of TNF-α and IL-10 was also observed in liver and skeletal muscle, whereas 
only selectively elevated levels of circulating IL-6 and TNF-α were observed in 
both genotypes. Consistent with the observations of elevated IL-6 and TNF-α 
levels in circulation, downstream signaling events mediated by IL-6 and 
TNF-α, such as phosphorylation of IκBα and STAT-3, were increased in liver 
and muscle under euglycemic-hyperinsulinemic clamp conditions. Thus, 
euglycemic-hyperinsulinemic clamp conditions promote an elevated 
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pro-inflammatory tone and thereby indicate an important contribution of IL-6 in 
maintaining glucose homeostasis during euglycemic-hyperinsulinemic clamp 
studies (83, 212). 
 
Although IL-6 seems to act as both pro-inflammatory as well as 
anti-inflammatory cytokine (213), our study reveals an overall clear 
anti-inflammatory role for IL-6 signaling in the liver. Consistent findings 
demonstrated that IL-6 acts as negative feedback regulator of inflammatory 
signaling pathways in macrophages. On the one hand, the stimulation of 
macrophages with IL-6 leads to the production of IL-1 receptor antagonists 
(IL-1Rα) as well as soluble TNF receptor p55 (TNFsRp55), thereby inhibiting 
the inflammatory response (214). On the other hand, IL-6 deficient 
macrophages were shown to have an increased inflammatory respone upon 
lipopolysaccharide stimulation, indicated by elevated expression of TNF-α 
(172), suggesting that IL-6 can function rather as anti- than pro-inflammatory 
cytokine to limit the inflammatory tone. 
 
However, in our study, ablation of hepatic IL-6 signaling promotes an 
activation of inflammatory cytokine expression in liver-resident macrophages 
(Kupffer cells), indicating an IL-6 dependent crosstalk of hepatocytes to the 
neighboring Kupffer cells to limit inflammation. The Kupffer cell activation in 
the in IL-6RαL-KO mice not only induces a hepatic inflammatory response, but 
also induces increased expression of IL-6, TNF-α and IL-10 in skeletal muscle 
and WAT, presumably as a consequence of increased Kupffer cell derived 
TNF-α.  
 
In addition to the role of hepatic IL-6 action in limiting local and systemic 
inflammation, this study also revealed the functional significance of Kupffer 
cell activation, which leads to increased TNF-α expression in the IL-6RαL-KO 
mice, resulting in impaired glucose homeostasis. Ablation of Kupffer cells or 
neutralization of TNF-α action in IL-6RαL-KO mice restored the impaired 
glucose tolerance in IL-6RαL-KO mice to normal. 
 
Discussion 
____________________________________________________________________________________________________________________________ 
 
 86 
However, whether the development of insulin resistance in IL-6RαL-KO mice is 
a consequence of systemic increased IL-6 concentrations leading to the 
subsequent activation of IL-6 signaling in other tissues than the liver cannot 
be excluded in this study. Nevertheless, unaltered STAT-3 phosphorylation in 
skeletal muscle of IL-6RαL-KO mice indicates a negliable effect of increased 
IL-6 action in skeletal muscle in the development of insulin resistance. 
 
Besides the elevated chronic systemic inflammation, which leads to the 
development of insulin resistance, our experiments also indicate that 
activation of proinflammatory signaling can simultaneously impair β-cell 
function. This is consistent with the notion that inflammatory cytokines, 
especially TNF-α, are able to inhibit insulin release from the β-cells (215, 
216). 
 
Given these complex effects of IL-6 signaling on hepatic metabolism and the 
initiation of a systemic inflammatory response upon inhibition of IL-6 signaling, 
caution should be warranted to potential diabetogenic side effects of newly 
evolving therapies aiming to interfere with IL-6 signaling to treat chronic 
inflammatory diseases, such as rheumatoid arthritis (217, 218). 
 
 
4.5 The role of hepatic MyD88 in energy homeostasis 
 
Recent data indicate that innate immune response pathways are involved in 
the development of obesity-associated insulin resistance (173). Although the 
molecular mechanisms, underlying the development of obesity-associated 
insulin resistance, are still not elucidated, recent observations suggest an 
unexpected role for MyD88 in preventing diabetes (177). In this study, the 
authors show that mice carrying MyD88 deficiency on a high fat diet (HFD) 
had increased circulating levels of insulin, leptin and cholesterol, as well as 
liver dysfunction. In our study, we could clearly demonstrate that mice lacking 
MyD88 exclusively in hepatocytes exhibit no alterations in energy 
homeostasis and body weight gain when fed a normal chow diet (NCD). 
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Additionally, lipid metabolism, glucose tolerance and insulin sensitivity were 
unchanged between MyD88L-KO and control mice, indicating that hepatic 
MyD88L-KO is not essential for maintaining both energy homeostasis and 
glucose homeostasis on NCD. Interestingly, it was previously shown that mice 
lacking systemic TLR4, which mainly transduce signaling via MyD88, were 
protected from FFA-induced insulin resistance upon 8 hour lipid infusion (113, 
219). Additional data reveal that MyD88 dependent signaling in the CNS is a 
key regulator of diet-induced leptin and insulin resistance in vivo, since 
MyD88ΔCNS mice are protected from HFD-induced weight gain and from the 
induction of leptin resistance by acute central application of palmitate (178). 
Therefore, an approach of investigating energy homeostasis with MyD88L-KO 
mice fed a HFD would be interesting.  
 
 
4.6 MyD88 dependent signaling in the liver promotes chemically induced 
HCC 
 
DEN-induced hepatocacinogenesis has given new insights into the 
development of liver cancer in humans. The MyD88 adaptor molecule of the 
TLR signaling cascade plays an essential role in TLR-mediated development 
of insulin resistance and liver carcinogenesis. Consistent with the 
observations of decreased DEN-induced tumor development in mice lacking 
MyD88 (118), our study reveals an important role of hepatocytes in this 
phenotype, since mice lacking hepatic MyD88 signaling exhibit a similarly 
decreased susceptibility to the development of chemically induced HCC 
formation, although other cells, e.g. Kupffer cells, are not affected in our 
model. Necrotic debris released by DEN-injured hepatocytes not only 
activates Kupffer cells, but also triggers immune cell infiltration in a MyD88 
dependent manner. To this end, MyD88L-KO mice exhibit reduced hepatic 
infiltration upon DEN challenge. Which mechanism accounts for the reduced 
immune cell attraction in MyD88L-KO mice is not clear, since the chemokines 
analyzed in this study appeared to be unaltered between the genotypes. 
Identification of factors, leading to the reduced hepatic infiltration upon DEN 
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challenge in MyD88L-KO mice, is important and will be performed in the near 
future. Moreover, while MyD88L-KO mice exhibit reduced markers of liver 
injury, the hepatotoxic effect of DEN is decreased, which in turn could reduce 
immune cell attraction.  
 
However, the induction of liver injury in MyD88L-KO mice was not IL-6 
dependent as shown previously (118), since IL-6 levels were unchanged 
between control and MyD88L-KO mice. Our data rather suggest an important 
role of the IL-6 class cytokine leukemia inhibitory factor (LIF). Whereas 
DEN-induced HCC development leads to activation of LIF expression in 
control animals, the MyD88L-KO mice show significantly decreased induction of 
this cytokine. Consistent with our findings, another study implies elevated LIF 
as HCC inducer (220). In this study, the authors show that miR-637 acted as 
a tumor-suppressor by the inhibition of LIF expression and thereby disruption 
of STAT-3 activation. While this might explain the phenotype in the latter 
model, this notion could not be applied to MyD88L-KO mice, since we did not 
observe an elevated DNA-binding capacity of STAT-3 due to increased LIF 
mRNA expression in control mice. Nevertheless, activation of STAT-3 was 
induced in HCC and upon acute DEN treatment. Possible reasons for the 
observations of unaltered DNA-binding capacity of STAT-3 in HCC could be 
the unaltered IL-6 mRNA expression, which is a really strong STAT-3 
activator and thus attenuate the increased LIF expression. Additionally, the 
determination of hepatic LIF at the protein level is essential in this context.  
 
Other mechanisms involved in decreased tumor formation in MyD88L-KO mice 
might be the impairment of NF-κB and MAPK signaling. The NF-κB and 
MAPK signaling pathways are connected and often deregulated in various 
types of tumors, including HCC (124). While ablation of NF-κB and p38 leads 
to hypersusceptibility to DEN-induced hepatocarcinogenesis by elevated JNK 
activation, the deletion of JNK in this context reverses the increased 
susceptibility to HCC upon DEN treatment (141). Additionally, previous 
studies indicate that the activation of MAPKs upon liver damage is mediated 
by MyD88 dependent TLR signaling (221, 222). Since the observations of 
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reduced p65 activation and simultaneously decreased JNK activation in 
hepatocytes of DEN-induced HCC in MyD88L-KO mice, we could demonstrate 
that activation of NF-κB and JNK signaling in the liver is dependent on hepatic 
MyD88 signaling after liver injury. Additionally, our study reveals a minor role 
of hepatic MyD88 in activating p38 and ERK upon DEN treatment. We also 
confirmed the relation of active JNK to the development of HCC (141), since 
reduced JNK activation goes along with decreased HCC in MyD88L-KO mice. 
However, the activation of JNK in early stages of tumor development occurred 
independent of MyD88 since acute DEN treatments for 4 h revealed JNK 
activation in MyD88L-KO mice similarly as control mice. So it seems, that 
elevation of JNK at the early phase of tumor development has no impact on 
MyD88 related reduction of tumor development, but at later stages of HCC.  
 
It was shown that cellular stress leads to JNK activation mediated by TNFR1. 
In contrast to previous studies, where liver injury upon DEN treatment was 
dependent on MyD88 signaling but not through TNFR1 (118), we observe a 
strong induction of TNFR1 upon DEN treatment, whereas accumulation of 
TNF-α mRNA was unaltered. Furthermore, the induction of TNFR mRNA 
expression was dependent on hepatic MyD88 signlaing, since MyD88L-KO 
mice show blunted TNFR1 mRNA expression in DEN-induced HCC. To define 
whether the reduction of JNK activation in HCC is due to higher sensitivity to 
TNF-induced apoptosis, needs more investigations.  
 
The molecular and cellular interactions in MyD88 dependent HCC 
development are still unclear. However, future studies will reveal whether the 
reduction in JNK signaling is responsible for the reduced tumor load. For this, 
we will overactivate JNK with a conditional transgene specifically in MyD88 
deficient hepatocytes.  
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5. Summary 
 
Over the last decade, obesity has been recognized as a chronic low 
inflammatory state that predisposes for the development of diseases, such as 
obesity-associated insulin resistance and cancer. The chronic low grade 
inflammation under obese conditions manifests not only as increase of 
inflammatory mediators, such as TNF-α and IL-6 in circulation, but also in 
elevated free fatty acids in the bloodstream. Though, this inflammatory 
condition has been shown to impair insulin action and to increase the 
incidence of cancer development. The liver specific contribution of IL-6 
signaling as well as TLR signaling through the essential adaptor molecule 
MyD88 in these processes remains unclear.  
 
To examine the role of hepatic IL-6 signaling in glucose homeostasis, we 
have conditionally inactivated the IL-6Rα in hepatocytes of mice (IL-6RαL-KO). 
While these animals showed no alterations in body weight gain and body fat 
content, IL-6RαL-KO mice developed systemic insulin resistance, manifested 
as attenuated insulin stimulated glucose transport in skeletal muscle and fat 
during hyperinsulinemic-euglycemic clamps. Insulin resistance in these mice 
developed in the presence of increased circulating levels of IL-6 and TNF-α 
that directly translated in enhanced activation of inflammatory signaling in liver 
and skeletal muscle, thereby impairing insulin action. Neutralization of TNF-α 
or ablation of Kupffer cells restored glucose tolerance in IL-6RαL-KO mice to 
normal, indicating that increased circulating TNF-α, derived from the Kupffer 
cells, impairs insulin action systemically. Thus, our results reveal an 
unexpected role for hepatic IL-6 signaling to limit hepatic inflammation and to 
protect from local and systemic insulin resistance. 
 
Moreover, TLR-mediated signaling was examined in the development of 
insulin resistance and HCC, using mice with hepatocyte-specific MyD88 
deficiency (MyD88L-KO mice). While glucose homeostasis was largely 
unaltered, these mice exhibited decreased liver damage, reduced hepatic 
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macrophage infiltration and a strong reduction in chemically induced 
hepatocellular carcinoma development. Interestingly, tumor livers of 
MyD88L-KO mice exhibit reduced JNK activation that could potentially account 
for the reduced liver tumorgenesis in these animals.  
 
Taken together, this study highlights the hepatic role of inflammatory IL-6 and 
TLR-induced signaling in the development of obesity-associated insulin 
resistance and hepatocellular carcinogenesis.  
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6. Zusammenfassung 
 
In den letzten zehn Jahren wurde Adipositas als chronischer 
Entzündungszustand anerkannt, der den Körper für die Entstehung von 
Krankheiten, wie Adipositas-assoziiete Insulinresistenz und Krebs, anfällig 
macht. Dieser chronische Entzündungszustand äussert sich nicht nur durch 
die Erhöhung von inflammatorischen Zytokinen, wie z.B. TNF-α und IL-6, 
sondern auch von freien Fettsäuren im Blut. Frühere Studien haben gezeigt, 
dass dieser Zustand zur Beeinträchtigung der Insulinwirkung und Erhöhung 
der Krebsprävalenz führt. 
 
Zur Untersuchung der Rolle des IL-6 Signaltransduktionsweges auf den 
Glukosehaushalt wurde das IL-6Rα Gen in Hepatozyten von Mäusen 
(IL-6RαL-KO) konditional inaktiviert. Während diese Mäuse sich nicht in ihrer 
Gewichtszunahme und ihrem Körperfett unterschieden, entwickelten die 
IL-6RαL-KO  Mäuse eine systemische Insulinresistenz, welche sich in 
Euglykämischen-Hyperinsulinämischen Clamp-Studien in einem gestörten 
Glukosetransport in die Skelettmuskulatur und ins Fettgewebe manifestierten. 
Diese resultierte aufgrund von erhöhter Konzentration der zirkulierenden 
Zytokinen IL-6 und TNF-α im Blutspiegel, welche zu einer ansteigenden 
Immunantwort in der Leber und in der Skelttmuskulatur führte. Die 
Neutralisation von TNF-α oder die Ablation der Kupffer-Zellen in IL-6RαL-KO  
Mäusen führten zu einer Normalisierung der Glukosetoleranz. Dadurch wurde 
gezeigt, dass die Beeinträchtigung der Insulinwirkung wahrscheinlich durch 
erhöhte TNF-α Ausschüttung aus Kupffer-Zellen zustande kommt. So zeigen 
unsere Ergebnisse eine unerwartete Rolle des leberspezifischen IL-6 
Signaltransduktionweges in der Verhinderung lokaler und systemischer 
Insulinresistenz, durch die Limitierung der leberspezifischen Inflammation. 
 
Darüber hinaus wurde die Rolle der TLR-vermittelten Signaltransduktion in 
der Entwicklung von Insulinresistenz und hepatozellulären Karzinomen, mit 
Hilfe von Mäusen denen Hepatozyten spezifisches MyD88 fehlt (MyD88L-KO), 
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untersucht. Während die Glukose Homeostase hauptsächlich unverändert 
war, zeigten diese Mäuse verminderten Leberschaden, verminderte Infiltration 
von Makrophagen in der Leber, so wie eine starke Reduktion von chemisch 
induzierten hepatozellulären Karzinomen. Interessanterweise war die 
Aktivierungen von JNK in den Tumor befallenen Lebern der MyD88L-KO 
Mäusen reduziert, was eventuell zur verminderten Ausbildung der 
Hepatozellulären Karzinomen in diesen Mäusen verantwortlich ist. 
 
Zusammenfassend kann man sagen, dass diese Studie deutliche Hinweise 
auf die leberspezifischen Rollen der IL-6 und TLR-vermittelten 
Signaltransduktion in der Ausbildung von Adipositas-assoziieter 
Insulinresistenz sowie hepatozellulären Karzinomen liefert.   
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